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ABSTRACT 
 
REPROGRAMMING THE RETINA: NEXT GENERATION STRATEGIES OF RETINAL 
NEUROPROTECTION AND GENE THERAPY VECTOR POTENCY ASSESSMENT 
Devin S. McDougald 
Jean Bennett M.D., Ph.D. 
Mutations within over 250 known genes are associated with inherited retinal degeneration. 
Clinical success following gene replacement therapy for Leber’s congenital amaurosis type 2 
establishes a platform for the development of downstream treatments targeting other forms of 
inherited and acquired ocular disease. Unfortunately, several challenges relevant to complex 
disease pathology and limitations of current gene transfer technologies impede the development 
of gene replacement for each specific form of retinal degeneration. Here we describe gene 
augmentation strategies mediated by recombinant AAV vectors that impede retinal degeneration 
in pre-clinical models of acquired and inherited vision loss. We demonstrate distinct 
neuroprotective effects upon retinal ganglion cell survival and function in experimental optic 
neuritis following AAV-mediated gene augmentation. Gene transfer of the antioxidant 
transcription factor, NRF2, improves RGC survival while overexpression of the pro-survival and 
anti-inflammatory protein, SIRT1, promotes preservation of visual function. In the context of 
inherited retinal disease, we show stimulation of anabolic metabolism following AKT3 gene 
transfer preserves photoreceptor viability and delays functional loss in a mouse model of retinitis 
pigmentosa. In addition to these neuroprotective strategies, we also describe an approach to 
improve the in vitro potency of AAV vectors that are restricted by tissue-specific regulatory 
elements. This strategy utilizes genome engineering based on CRISPR/Cas9 gene activation to 
reprogram cell lines to specifically and potently express tissue-specific promoters of interest from 
AAV vectors.  
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CHAPTER 1 Introduction 
 
Organization and composition of the mammalian visual system 
 The retina is a thin layer of neural tissue situated at the back the eye that is composed of 
specialized cellular layers that function in a concerted fashion to convert photo-chemical stimuli 
into neural impulses that travel to the brain and mediate the sensory perception known as vision. 
The mammalian retina contains three layers of neurons separated by two additional layers of 
synaptic connections (Figure 1.1). The outer retina is composed of the retinal pigment epithelium 
(RPE) and photoreceptor layer. The RPE is the outer most population of retinal cell types and 
provides structural 
integrity and 
support to cells of 
the neural retina. 
The RPE mediates 
the transport of 
various nutrients, 
ions, and growth 
factors from 
systemic circulation via the choroidal vasculature. In addition, RPE cells supply critical 
components in the visual cycle maintenance and are essential for the phagocytosis, breakdown, 
and recycling of photoreceptor outer segments (Sparrow et al., 2010). Photoreceptors are a 
specialized collection of sensory neurons that capture photons of light as the initial step in the 
photo-transduction cascade. In mice and humans, photoreceptors account for approximately 70% 
of retinal cell types and are divided into two major subtypes: rods and cones. Rods are 
responsible for visual processing in low light (scotopic) conditions mediated by the photo-
sensitive pigment, rhodopsin. Cone photoreceptors are responsible for mediating complex 
features of vision associated with photopic conditions (bright light), color, and high 
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resolution/acuity. In vertebrates, cone cells are further divided into two or three subtypes based 
upon their specific photo-transduction pigment and corresponding responses to various 
wavelengths of light. For example, humans contain three cone subtypes that are responsive to 
long (red; L-opsin), medium (green; M-opsin), or short (blue; S-opsin) wavelengths of light (Kolb, 
2007). In both mice and humans, rods vastly outnumber the cone cells approximately 30:1 (mice) 
and 20:1 (humans). Moreover, the anatomical and spatial distribution of rods and cones vary 
between vertebrate species. Humans and other higher order primates contain a fovea which is 
composed of cones located in the central retina responsible for high acuity visual processing, 
whereas rods dominate the retinal periphery (Kolb, 2007). From a structural perspective, 
photoreceptors are composed of four distinct components: outer segment, inner segment, cell 
body, and synaptic terminal. The outer segment is a specialized primary cilium composed of 
several membranous discs saturated with visual pigments and other essential components 
involved in light capture and signal transduction. The inner segment contains the golgi, 
mitochondria, and endoplasmic reticulum to support the incredible energetic and metabolic 
demands of the photoreceptor (Baker et al., 2013). Synaptic terminals provide the critical link in 
transmission of visual signals from the photoreceptor to second order neurons occupying the 
inner retina (Kolb, 2007).  
Cell types of the inner retinal layer (INL) include bipolar cells, horizontal cells, and 
amacrine cells. Bipolar cells function as second order neurons and are critical for transmitting 
signals from the photoreceptors to the ganglion cells via synaptic connections of the inner 
plexiform layer (IPL). Bipolar cells are typically separated into two major subclasses designated 
as “ON” or “OFF” cells. Glutamate release from photoreceptors functions as a neurotransmitter 
and modulates the activity of ON and OFF bipolar cells. In the dark, glutamate release 
hyperpolarizes (inhibits) the activity of ON bipolar cells and depolarizes (activates) OFF cells 
(Kolb, 2003). Conversely, hyperpolarization of the photoreceptor following light capture reduces 
glutamate release leading to depolarization (excitation) of ON bipolar cells and hyperpolarization 
of OFF cells (Kolb, 2003). ON and OFF bipolar cells can be further subdivided based upon their 
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connectivity with photoreceptors via synapses that constitute the outer plexiform layer (IPL). 
Certain subclasses of bipolar cells will synapse with rods while others form connections with 
multiple or single cone subtypes (Euler et al., 2014). Horizontal cells and amacrine cells function 
as inhibitory neurons that integrate and regulate inputs between the photoreceptors and retinal 
ganglion cells (Kolb, 2007). Retinal ganglion cells (RGCs) are the terminal neuron of the retina 
and mediate the transfer of visual information to the brain. Axonal projections emanating from the 
RGCs innervate and form the optic nerve, which provides a physical connection between the 
retina and visual centers of the brain. 
 
Inherited retinal degenerations (IRDs) 
 Given the incredibly complex and coordinated fashion through which retinal neurons 
process, interpret, and transmit visual input, it is unsurprising that defects within very discrete 
components can mediate profound consequences upon visual function. Mutations within over 250 
genes are associated with retinal degeneration (Bennett, 2017; RetNet). Mendelian forms affect 
approximately 1 in 2000-3000 
individuals with the majority of 
these manifestations resulting 
from dysfunction and 
subsequent death of 
photoreceptors (Wright et al., 
2010). Numerous mechanisms 
are implicated in photoreceptor 
cell death ranging from retinal-
specific functions to ubiquitous cellular mechanisms such as defects in photo-transduction, the 
visual cycle, or outer segment maintenance/stability. Perturbations in ubiquitous cellular 
processes including pre-mRNA splicing, signaling pathways, mitochondrial function, lipid 
metabolism, and many others (Figure 1.2) also contribute to photoreceptor degeneration (Wright 
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et al., 2010). Retinitis pigmentosa accounts for the largest and most genetically diverse group of 
inherited photoreceptor degenerations and is characterized by the onset of rod degeneration and 
culminating with the progressive demise of cones in later stage disease (Punzo et al., 2012). The 
genetics, mechanisms of disease, and potential therapeutic strategies for retinitis pigmentosa will 
be discussed extensively in Chapter 3. Other IRDs, such as Leber’s congenital amaurosis (LCA), 
display early onset vision loss typically within the first year of life resulting from pathogenic 
mutations within seventeen known genes with functions associated with the visual cycle (ex. 
RPE65, RDH12), connecting cilium structure and transport (ex. CEP290, LCA5), and 
photoreceptor development (ex. CRX, CRB1). Other IRDs are characterized by phenotypes that 
primarily affect one photoreceptor subtype including congenital stationary night blindness 
(primarily rod involvement) or cone dystrophies (cone degeneration) (Veleri et al., 2015). In the 
case of many IRDs, the kinetics of vision loss and retinal degeneration can be highly variable 
between patients depending upon the affected gene and the severity of the pathogenic mutation. 
Moreover, different mutations with the same gene can be differentially diagnosed based on the 
clinical presentation. Advancements in genetic testing and DNA sequencing technologies allow 
us to increase our knowledge of these complex genotype-phenotype correlations associated with 
IRDs. Understanding these relationships will provide critical information for improving the 
accuracy and timing of a clinical diagnosis, patient-specific prognosis, and perhaps the 
opportunity for therapeutic intervention (Bryant et al., 2017).  
 
Acquired retinal degeneration 
 In addition to mendelian forms of vision loss that typically manifest early in life, other 
retinal diseases may arise later due to complex environmental, genetic, and age-related 
determinants. Glaucoma is an optic neuropathy characterized by the loss of retinal ganglion cells 
and is the leading form of irreversible blindness throughout the world (Weinreb et al., 2014). 
Numerous mechanisms are implicated in the development of glaucoma including elevation in 
intraocular pressure (IOP) thereby compressing optic nerve fibers/disrupting axonal transport, 
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dysregulation of autophagic flux within RGCs, vascular alterations, and mitochondrial dysfunction 
(Davis et al., 2016).  
Age-related macular degeneration (AMD) is the primary cause of blindness within the 
elderly and is an acquired disease that affects the RPE but leads to secondary degeneration of 
photoreceptors (Ambati et al., 2012). Early signs of AMD involve the accumulation of extracellular 
aggregates known as drusen. This typically precedes RPE degeneration. AMD is subdivided into 
two forms termed “dry” or “wet.” Wet AMD is characterized by an additional phenotype beyond 
primary RPE degeneration: outgrowth and invasion of immature choroidal blood vessels into the 
outer retina, known as choroidal neovascularization (CNV). These vessels disrupt features of 
retinal homeostasis by leaking various components into the neural retina (Ambati et al., 2012). 
Other acquired ocular conditions may arise as secondary features of a broader disease process. 
In Chapter 2, I will provide a detailed description of one such condition, called optic neuritis, which 
is characterized by inflammation and demyelination of the optic nerve. Optic neuritis is commonly 
encountered at the onset of multiple sclerosis. Current treatment strategies for these conditions 
are aimed at attenuating pathological processes. Medications for glaucoma are aimed at reducing 
intraocular pressure via hypotensive eyedrops, oral drugs, or laser trabeculoplasty (Weinreb et 
al., 2014). Wet AMD is treated by intravitreal administration of antibodies directed against VEGF-
A, which diminishes vascular outgrowth and stabilizes vision in most patients. Unfortunately, 
there are currently no effective treatment strategies for the more prevalent dry AMD (Ambati et 
al., 2012). In most of these disease scenarios where treatments are available, patients must 
adhere to strict treatment regimens to prevent further retinal degeneration and associated vision 
loss. Furthermore, these strategies do not address the underlying features driving 
neurodegeneration of the cell type exhibiting pathology.  
  
Gene therapy for retinal degenerative diseases 
The practice of gene therapy is an ongoing subject of intense scientific and medical 
investigation that has spanned well over forty years. Friedmann & Roblin (1972) introduced the 
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concept and transformative potential of gene therapy to ameliorate substantial forms of human 
suffering in their landmark article published in the journal, Science. However, the authors also 
cautioned against its immediate application in human clinical studies given the incomplete 
understanding of basic processes governing gene regulation, delivery of recombinant DNA to 
human cells, and fundamental molecular mechanisms of many inherited diseases. Decades that 
followed observed rapid advancements in each of these specific areas. The first retinal disease 
gene involved in a form of X-linked retinitis pigmentosa was successfully mapped in 1984 
(Bhattacharya et al., 
1984). Continued 
advancements in DNA 
cloning, sequencing, and 
results of the human 
genome project propelled 
unprecedented discovery 
and functional 
interrogation of 
thousands of human disease genes (International Human Genome Sequencing Consortium, 
2001). Because of such efforts, we have successfully identified over 250 genes associated with 
inherited retinal degeneration (Bennett, 2017; RetNet) (Figure 1.3). Possibly the most critical 
advancements in priming gene therapy for clinical translation involved the discovery and 
engineering of safe and effective gene delivery vehicles, referred to as “vectors,” for targeting 
diverse cellular and tissue populations (Thomas et al., 2003). The most efficient vector platforms 
for in vivo directed gene therapy are derived from human and primate viruses. Viral vectors are 
composed of two major functional components: the capsid and expression cassette. The viral 
capsid dictates tropism for specific cell types (Srivastava, 2016). Engineering of the vector 
expression cassette includes removal of viral elements encoding structural or functional features 
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that aid in their replication cycle. Such elements are replaced with transgenes that encode cDNA 
sequences of therapeutic interest and various regulatory elements (Figure 1.4).  
The eye provides a favorable environment to interrogate the efficacy of gene-based 
treatments. The small anatomical size of the organ allows the use of small vector volumes and 
doses to achieve substantial targeting of retinal cell types. In addition, the presence of the second 
eye enables the use of a within-subject control to determine the effects of an experimental 
treatment. Moreover, ocular health and therapeutic outcomes can be easily assessed with 
various noninvasive imaging techniques including fundoscopy and optical coherence tomography 
(OCT). Finally, the eye is considered an “immunoprivileged” compartment, meaning it can tolerate 
the introduction of foreign antigens, such as viral vectors, without eliciting a robust inflammatory 
response (Willett & Bennett, 2013). This feature is largely due to the presence of the blood-retinal 
barrier, which is composed of retinal pigment epithelia (RPE) and the retinal vascular 
endothelium. Tight junctions between the RPE prevent contact between the neural retina and 
systemic circulation of the choroid (Forrester et al., 2012). RPE cells also secrete various soluble 
factors such as CD95L (fas ligand), that induce effector T cell apoptosis, thus contributing another 
layer of immune modulation (Jorgensen et al., 1998). Moreover, the presence of distinct proteins 
such as B7-1 and B7-2 on the surface of different retinal cell types are involved in the conversion 
of naïve T cells to regulatory T cells (Tregs), which contribute additional immunosuppressive 
properties (Stein-Streilein & Taylor, 2007; DiCarlo et al., 2018).  
 
AAV-mediated gene therapy for Leber’s congenital amaurosis type 2 (LCA2) 
 Decades of scientific inquiry to identify retinal disease genes, animal models that 
accurately reflect human disease conditions, and the continued development of safe and durable 
vector platforms culminated in proof-of-concept studies and subsequently the first human clinical 
trials for an inherited form of vision loss (Bainbridge et al., 2008; Hauswirth et al., 2008; Maguire 
et al., 2008). Initial studies interrogated the pre-clinical efficacy of a gene replacement therapy for 
an inherited retinal disease in animal models of Leber’s congenital amaurosis type 2 (LCA2) 
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using an adeno-associated virus serotype 2 (AAV2) vector as the gene delivery vehicle. Similar to 
the human disease, these animals contain loss-of-function mutations in the RPE65 gene, which 
encodes an enzyme critical for the conversion of all-trans retinal to 11-cis retinol in the visual 
cycle. Acland et al. (2001) was the first to demonstrate visual recovery in a naturally occurring 
dog model of LCA2 using AAV2-mediated gene replacement of RPE65. Downstream 
investigations achieved similar findings within the same dog model as well as the Rpe65-/- mouse 
(Dejneka et al., 2004; Acland et al., 2005; Jacobson et al., 2006; Bennicelli et al., 2008), which 
provided the pre-clinical framework for translation to human clinical testing. Initial clinical studies 
examined safety and efficacy of AAV2 vector delivery to the subretinal space in a small cohort of 
patients diagnosed with LCA2. Patients exhibited no adverse events to the AAV2 vector at a dose 
of 1.5x1010 vector genomes. Moreover, patients showed improvement in pupillary light reflex and 
visual acuity (Maguire et al., 2008). A phase 1 dose-escalation trial in 12 patients between ages 8 
to 44 years revealed age-dependent effects upon visual recovery following treatment with 
younger individuals demonstrating the greatest improvement in vision (Maguire et al., 2009). 
Moreover, this trial reinforced the robust safety and efficacy data observed in the initial cohort of 
patients (Maguire et al., 2008; Maguire et al., 2009). Furthermore, the effects upon visual function 
remained durable over time (Simonelli et al., 2010; Bennett et al., 2016). In addition to recovery of 
retinal function, incredibly, the effects of gene replacement also led to reactivation and 
reorganization of synaptic connectivity within the visual cortex, suggesting the durable effects of 
gene replacement may also impact neural plasticity (Ashtari et al., 2011; Ashtari et al., 2015). 
Based on the robust safety and efficacy profile demonstrated in the phase 1 studies, a phase 3 
trial enrolling 31 total patients was initiated (Russell et al., 2017). The AAV2 vector used in these 
studies was ultimately approved by the US Food & Drug Administration in December 2017 under 
the commercial name, Voretigene neparvovec-ryzl, or more simply, Luxturna. This landmark 
scientific and medical achievement sets the stage for the development of additional gene therapy 
products targeting other forms of inherited and acquired vision loss.  
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Gene transfer with adeno-associated virus (AAV) vectors 
 Vectors based upon recombinant adeno-associated virus (AAV) have become the current 
standard for targeting retinal cell populations safely and effectively (Bennett, 2017). AAV was first 
identified as a contaminant of adenovirus preparations (Atchison et al., 1965). The AAV genome 
consists of a small, single-stranded DNA molecule of approximately 4.7 kilobases in length 
encoding two genes flanked by two 145 base pair inverted terminal repeats (ITRs) (Figure 1.4). 
The Rep gene encodes various proteins (Rep40, Rep52, Rep68, Rep78) associated with viral 
DNA replication and packaging, whereas the Cap gene encodes three structural proteins involved 
in assembly of the viral capsid (VP1, VP2, VP3) (Salganik et al., 2015). Recombinant AAV (rAAV) 
genomes can be generated through excision of the Rep and Cap genes and inclusion of a 
transgene cassette between the ITR sequences (Figure 1.4). These recombinant genomes are 
readily packaged into infectious AAV particles by supplying the Rep and Cap genes in trans and 
in the presence of adenovirus (Tratschin et al., 1984). Downstream investigations elucidated the 
specific adenovirus factors that contribute to the AAV replicative cycle (Ferrari et al., 1997; Xiao 
et al., 1998). Identification of these factors led to development of the “triple transfection” method 
in which three plasmids encoding the AAV expression cassette, Rep/Cap genes, and the 
adenoviral “helper” genes (respectively) are transiently transfected into human embryonic kidney 
293 cells (HEK293). This has become the standard procedure for generation of research and 
clinical grade rAAV vectors (Mingozzi & High, 2011).  
AAV exhibits several favorable properties as a gene transfer vector for in vivo directed 
applications. Foremost, the wild-type virus has not been associated with any human disease. This 
is a unique feature compared to other conventional viral vector platforms including lentivirus 
(HIV/AIDS), HSV-1 (herpes), and adenovirus (respiratory infections). While the wild-type virus 
has been shown to preferentially integrate into a specific genomic region located on the long arm 
of chromosome 19 (19q13-qter), later termed the AAV safe harbor locus (AAVS1), this process 
occurs at an exceptionally low frequency (approximately 0.1%) (Deyle et al, 2009; McCarty et al., 
2004). In most cases, the incoming single-stranded AAV genome is converted to a non-
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integrating, double-stranded circular episome that provides durable transgene expression in 
quiescent cell types. This feature reduces the possibility of insertional mutagenesis commonly 
associated with other vector platforms including lentiviral and retroviral vectors (Bokhoven et al., 
2009; Uren et al., 2005). Compared to other viral vectors, rAAV exhibits a low immunogenic 
profile perhaps due to its relatively poor transduction efficiency of antigen presenting cells (APCs) 
(Mays et al., 2014) or its complete lack of viral-associated genes (Basner-Tschakarjan et al., 
2014). Despite its weak immunogenicity, the immune system can still detect other vector 
components including the capsid proteins, vector genome, and transgene products. Thus 
components of humoral immunity, including T cells and pre-existing neutralizing antibodies, may 
limit the efficacy of gene transfer and lead to the elimination of successfully transduced cells 
(Louis Jeune et al., 2013). Moreover, this presents a substantial challenge for the prospect of 
vector re-administration (Mingozzi & High, 2013).  
 
 
 
 
 
 
 
 
 
 
 
Ocular gene delivery: vectors, routes of administration, and cell targeting considerations 
Gene transfer vectors are introduced in clinical trials to retinal cell types via two routes of 
administration. The intravitreal injection is a common outpatient procedure by which a small 
needle is inserted through the pars plana followed by release of the reagent into the vitreous 
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cavity (Figure 1.5). This approach is used to administer medication for a variety of retinal 
conditions including age-related macular degeneration (AMD) and diabetic retinopathy. Delivery 
of AAV vectors with this injection approach has revealed tropism for retinal ganglion cells (RGCs) 
and their axons projecting through the optic nerve. Moreover, various studies have utilized this 
combination of vector and delivery approach to demonstrate RGC protection in various animal 
models of optic neuropathy (Qi & Lewin et al., 2007; Qi & Sun et al., 2007; Talla et al., 2013; Talla 
et al., 2014; Talla et al., 2015; McDougald et al., 2018). The insufficient transduction of outer 
retinal cell types, including photoreceptors and RPE, through intravitreal administration is partly 
due to presence of the inner limiting membrane (ILM), which serves as a basement membrane in 
the eye and provides physical separation of the retina and vitreous humor. Thus, the ILM likely 
acts as a barrier for the penetration of viral particles (Dalkara et al., 2009). Moreover, the 
structure is coated with various extracellular matrix proteins that may bind and sequester vector 
particles from reaching the retina (Candiello et al., 2007). Various studies suggest outer retinal 
targeting with gene transfer vectors can be enhanced through pharmacological digestion or 
physical removal of the ILM (Dalkara et al., 2009; Takahashi et al., 2017). However, sufficient 
targeting of photoreceptors and other cell types localized to the outer retina with conventional 
AAV vectors relies upon delivery of these particles to the subretinal space. This approach 
involves a somewhat invasive procedure in which the physician delicately places the injection 
needle between the neural retina and retinal pigment epithelium (Figure 1.5). Vector preparation 
is dispensed in a controlled fashion and generates a localized retinal detachment commonly 
referred to as a “subretinal bleb.” This region typically re-attaches to the underlying RPE within a 
few days.  
Beyond the route of administration, other features that must be taken into consideration 
to achieve targeting of a specific retinal cell population include selection of an appropriate capsid 
and regulatory elements. The amino acid sequence of the Cap gene dictates the tropism of the 
rAAV particle. Pioneering studies examined the retinal tropism of AAV2 encoding reporter genes 
under the regulation of ubiquitous promoters via intravitreal or subretinal delivery. This vector was 
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shown to readily transduce retinal ganglion cells and optic nerve following intravitreal 
administration (Dudus et al., 1999). If the vector is injected within the subretinal space, it displays 
exceptional tropism for retinal pigment epithelia (RPE) (Bennett et al., 1997). Downstream studies 
examined the retinal tropism of various naturally isolated and rationally designed AAV capsids. 
Vectors such as AAV5, AAV8, and AAV9 demonstrate efficient targeting of photoreceptors 
following subretinal delivery (Lotery et al., 2003; Lebherz et al., 2008; Vandenberghe et al., 2011; 
Vandenberghe et al., 2013). Since photoreceptors are the primary cell type affected in the 
majority of IRDs, the emergence of these vectors expanded the utility of AAV-mediated gene 
replacement to target these diseases. Additional investigations performed site directed 
mutagenesis of surface exposed tyrosine residues within the AAV2 capsid sequence to broaden 
its retinal tropism and utility. It is suggested that changing these tyrosine residues protects vector 
particles from ubiquitination and proteasome-mediated degradation thus enhancing successful 
transduction events (Petrs-Silva et al., 2009; Petrs-Silva et al., 2011; Mowat et al., 2014). More 
recent efforts aimed to identify synthetic AAV capsids via in vivo evolution/selection to achieve 
outer retinal targeting with the less invasive intravitreal delivery approach (Boyd RF et al., 2016; 
Dalkara et al., 2013; Kay et al., 2013). However, anatomical differences between species 
continue to pose formidable barriers for translation of these vectors with respect to penetration of 
retinal cell layers after intravitreal injection and cellular specificity (Ramachandran et al., 2017).  
In addition to capsid selection, features of the AAV expression cassette can be modified 
to drive tissue-selective transgene expression. Numerous promoter elements are available to 
drive cell-specific expression within distinct retinal cell types including photoreceptors, bipolar 
cells, and retinal ganglion cells (Flannery et al., 1997; Lu et al., 2016; Chaffiol et al., 2017). These 
regulatory elements provide an additional layer of safety by reducing the possibility of off target 
transgene expression within otherwise healthy cell types. Many of these promoter elements will 
be described in subsequent chapters. Collectively, selection of the appropriate capsid, regulatory 
elements, and delivery route allows precise targeting of a specific retinal cell population with gene 
transfer. 
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Limitations of AAV-mediated gene replacement therapies for ocular disease 
 Despite the overwhelming pre-clinical and clinical evidence to support the continued 
development of AAV-based gene replacement for various ocular diseases, features associated 
with complex disease pathology and biophysical limitations of rAAV vectors impede the 
application of such strategies for many inherited and acquired conditions. The “Achilles heel” of 
the AAV gene transfer platform concerns its limited DNA packaging capacity of approximately five 
kilobases. Numerous genes implicated in IRDs unfortunately exceed this size restriction, and thus 
are not candidates for gene replacement using conventional AAV vectors. Several efforts are 
underway to deliver genes using alternative vector platforms that can accommodate these large 
cDNA and promoter sequences. However, these systems present additional challenges including 
unstable gene expression patterns, immunogenic concerns, and insufficient targeting of the 
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desired cell population (Thomas et al., 2003). Another strategy to deliver large transgene 
cassettes utilizes the delivery of two AAV vectors that each encode one half of the transgene 
sequence. In this scenario, the two vector sets may undergo homologous recombination and 
reconstitute the fully intact cDNA sequence (Hirsch et al., 2016; Carvalho et al., 2017). Moreover, 
other strategies harness the advantages of a single AAV to deliver partial coding sequences 
capable of editing endogenous pre-mRNA transcripts through a process known as spliceosome-
mediated pre-mRNA trans-splicing (Berger et al., 2015; Dooley et al., 2018). Unfortunately, the 
current iterations of these technologies display particularly low efficiency in their respective 
processes to mediate a therapeutic effect (Carvalho et al., 2017; Dooley et al., 2018).    
 
Neuroprotective gene transfer strategies for retinal degeneration 
While gene replacement is an attractive strategy to ameliorate ocular pathology 
associated with mendelian forms of vision loss, other forms of retinal degeneration as described 
previously are characterized by disease etiologies due to complex genetic and environmental 
factors rather than single gene defects. Furthermore, limitations of the conventional vector 
systems as described in the previous section also present substantial challenges to address 
certain monogenic conditions.  It may be possible to alleviate or slow retinal degeneration in 
many inherited or acquired forms of ocular disease by targeting “conserved” features of the 
pathological process. This concept, often referred to as “neuroprotection,” utilizes 
pharmacological or gene transfer strategies to counteract common mechanisms that lead to 
progressive neurodegeneration. In the context of retinal degeneration, trophic factors such as 
ciliary neurotrophic factor (CNTF) and rod-derived cone viability factor (RdCVF) have been the 
subject of rigorous basic and translational research investigation within several inherited and 
acquired disease models (Liang et al., 2001; Maier et al., 2004; Ait-ali et al., 2015; Byrne et al., 
2015). Other strategies involve direct manipulation or reprogramming of cellular pathways by 
targeting critical mechanisms involved in the degenerative process. Several candidate 
interventions mitigate oxidative damage by direct scavenging of reactive oxygen species or 
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manipulation of gene expression programs associated with antioxidant defense (Qi & Lewin et al., 
2007; Qi & Sun et al., 2007; Xiong et al., 2015; Liang et al., 2017; McDougald et al., 2018). Other 
reagents non-specifically impede cell death by interrupting key components in the apoptotic 
signaling cascade (Petrin et al., 2003; Leonard et al., 2007). Finally, other strategies induce large 
scale reprogramming of key metabolic pathways that become dysregulated during disease 
progression (Venkatesh et al., 2015; Zhang & Justus et al., 2016; Zhang & Du et al., 2016; Rajala 
et al., 2018).   
 
Thesis aims 
 My thesis research examined novel neuroprotective strategies in pre-clinical models of 
retinal degeneration utilizing AAV-mediated gene transfer. Specifically, Chapters 2 and 3 will 
examine strategies to impede retinal degeneration in complex forms of acquired and inherited 
vision loss through reprogramming the metabolism of retinal neurons with gene augmentation. 
Chapter 2 will focus on the design and testing of potential therapeutic interventions to attenuate 
inflammatory and oxidative stress-induced retinal degeneration in a mouse model of optic 
neuritis. Chapter 3 describes a neuroprotective strategy to delay photoreceptor degeneration in a 
mouse model of retinitis pigmentosa. This approach involves stimulating pathways associated 
with anabolic metabolism and cell survival to nonspecifically impede photoreceptor death during 
disease progression.      
 Later in my studies, I became interested in the development of translational research 
tools to more accurately characterize the effects of gene transfer vectors driven by tissue or cell-
specific regulatory elements. Specifically, I engineered cell-based platforms to interrogate the 
function and potency of AAV vectors regulated by promoters that are only active within 
mammalian photoreceptors. Potency assays are an essential component in all phases of a drug 
development timeline and ensure purity, stability, and function of the product. One of the 
underappreciated yet key impediments in developing cell-based potency assays for gene therapy 
products concerns the use of tissue or cell-specific promoters driving transgene expression. In 
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many cases, these elements display robust expression and specificity in vivo but exceptionally 
poor activity across several well characterized cell lines, thus hindering our ability to assess 
vector expression and potency in a cell-based setting. Chapter 4 will discuss a genome 
engineering approach that effectively and robustly activates photoreceptor-specific promoters 
from AAV vectors.   
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CHAPTER 2 Stimulating anti-inflammatory/antioxidant pathways in experimental optic 
neuritis with AAV-mediated gene transfer  
 
Multiple sclerosis: clinical phenotype and genetics 
Multiple sclerosis is a chronic neuroinflammatory disease characterized by infiltration of 
the central nervous system by autoimmune effector cells targeting conserved components of 
neural tissue such as myelin and oligodendrocytes. Extensive demyelination, axonal 
degeneration, and neuronal death implements a phenotype of progressive neurological 
impairment and physical disability (Dendrou et al., 2015; Mahad et al., 2015). While disease 
presentation is highly heterogeneous, common clinical symptoms include sensory deficits, 
fatigue, pain, cognitive 
decline, and loss of mobility. 
Most patients are diagnosed 
with relapsing-remitting MS 
(RRMS), which is 
characterized by the onset of 
recurrent neurological defects 
followed by a phase of 
recovery. The disease varies 
between patients with respect 
to episode frequency and 
duration. Patients with RRMS 
enter a second phase of 
disease termed secondary 
progressive MS (SPMS) which is characterized by a steady and permanent neurological decline 
in the absence of clinical relapses (Mahad et al., 2015). Approximately ten percent of patients 
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experience primary progressive MS (PPMS). Age of onset typically begins in the second or third 
decades for RRMS patients while PPMS manifests later in life.  
MS is largely considered an autoimmune disease with arms of both innate and adaptive 
immunity contributing to the neurodegenerative process. The disease is largely thought to be 
driven by the CD4+ T cell response based upon data from animal models of MS. Immunization of 
animals with components to generate an auto-inflammatory response against conserved neuronal 
antigens stimulates a CD4+ T cell response. Moreover, these cells can be adoptively transferred 
to naïve animals and prompt disease progression (Pettinelli et al., 1981), whereas antibody 
transfer does not generate a similar phenotype. CD8+ T cells mediate direct cytotoxicity following 
antigen recognition upon oligodendrocytes (Huseby et al., 2001; Sun et al., 2001; Na et al., 2008; 
Saxena et al., 2008; Mahad et al., 2015). Components of humoral immunity, including B cells and 
plasma cells, are also found within active MS lesions and secrete pathogenic antibodies that 
amplify the pro-inflammatory environment (Weber et al., 2011). Interestingly, the target antigens 
of antibodies in MS remain largely unknown. However, treatment of MS models with monoclonal 
antibodies directed against myelin oligodendrocyte glycoprotein (MOG) was shown to exacerbate 
the severity of disease progression (Linington et al., 1998). Innate immune responses in MS are 
mediated primarily by microglia within the lesion. These cells secrete various pro-inflammatory 
factors and exhibit a process known as oxidative burst that amplifies critical mechanisms of 
neurodegeneration including oxidative injury, mitochondrial stress, and ultimately neuronal energy 
failure, which will be discussed in further detail later in this chapter.  
Despite decades of research, a central “trigger” of MS onset is largely undefined but likely 
influenced by a combination of complex genetic risk factors and environmental cues. Variations 
within numerous immune loci such as HLA, IL-2Rα, and IL-7Rα are implicated in genetic 
predisposition to MS (Sospedra et al., 2016). A recent study combined whole exome sequencing 
with homozygosity mapping to identify a recessive missense mutation in the NLRP1 gene as a 
causative variant for familial MS. This gene encodes a critical sensory component involved in 
inflammasome-associated innate immune function. Interestingly, pathogenic mutations in a 
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related gene (NLRP3) are associated with other rare autoimmune syndromes (Maver et al., 2017) 
further supporting involvement/dysregulation of the inflammasome and other inflammatory 
pathways in autoimmune disease pathogenesis. Non-genetic risk factors for MS acquisition are 
mostly undefined from a mechanistic standpoint. However, several external factors including 
lifestyle choices, behavior, and exposure to certain infections are proposed to influence disease 
onset (Coo et al., 2004).    
 
Optic neuritis 
Optic neuritis is a condition commonly associated with multiple sclerosis and involves 
acute episodes of visual impairment mediated via inflammation and demyelination of the optic 
nerve (Kale, 2016). Extensive demyelination and axonal degeneration may culminate in 
permanent vision loss corresponding with the loss of retinal ganglion cells (RGCs) whose axons 
innervate and form the optic nerve (Costello et al., 2006; Fisher et al., 2006; Trip et al., 2005). 
Patients typically experience unilateral vision loss associated with orbital pain eye movement. 
These features correspond with decreased visual acuity in which two-thirds of patients register a 
visual acuity below 0.5 (0 = no light perception, ≥1 = normal). Fundoscopic examination is normal 
in most patients, but the optic disc may appear slightly edematous in the affected eye(s) (Wilhelm 
et al., 2015). Typically, visual function improves a few weeks following an episode of optic neuritis 
with visual acuity improving to normal in most patients. However, approximately 6% of patients 
still experience reduced visual acuity several months after disease presentation (Beck et al., 
1992; Wilhelm et al., 2015).  
 
Treatment strategies for multiple sclerosis & optic neuritis 
Conventional treatments for MS and optic neuritis are directed at managing the 
inflammatory response. A large multicenter, randomized clinical trial examined the efficacy of 
corticosteroids for the treatment of relapsing optic neuritis via intravenous or oral routes of 
administration (Beck et al., 2002). The high dose intravenous cohort demonstrated faster visual 
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recovery but no change in long-term visual outcomes compared to placebo treated controls. 
Patients administered oral doses showed no improvement in visual outcomes and, surprisingly, 
increased the risk of new episodes (Beck et al., 2002). Furthermore, another investigation 
concluded that the use of corticosteroids did not prevent optic nerve degeneration in acute optic 
neuritis (Hickman et al., 2003). Subsequent reports suggest there is no definitive evidence to 
support the use of corticosteroids to achieve normal visual recovery (Gal et al., 2015).  
In addition to corticosteroids, treatment with interferon-β has been extensively studied 
and demonstrated partial therapeutic efficacy particularly in RRMS (Paty et al., 1993; Jacobs et 
al., 1996; Ebers et al., 1998; Rog et al., 2006). Interferon-β is a cytokine that binds to the 
heterodimeric surface receptor, IFNAR1/2, and mediates a signal transduction cascade via the 
JAK/STAT pathway (Rudick et al., 2011). Signaling components form an activated transcriptional 
complex that translocates to the nucleus and modulates expression of genes containing 
interferon sensitive response elements (ISRE). While the exact function and influence of these 
gene expression programs in MS pathogenesis are largely uncharacterized, many of these 
products are associated with putative therapeutic responses including the activation of antiviral 
mechanisms, modulation of T cell activity, and stimulation of anti-inflammatory pathways (Rudick 
et al., 2011). Three formulations of interferon-β have been approved for the treatment of RRMS 
(Avonex, Betaferon, and Rebif). These treatments demonstrated an approximately 30% reduction 
in relapse rates, reduced development of new lesions as measured via MRI, and delayed the 
progression towards MS in the case of patients with clinically isolated syndromes (Paty et al., 
1993; Jacobs et al., 1996; Ebers et al., 1998; Rog et al., 2006). While interferon-β-based 
therapies do provide partial therapeutic efficacy in RRMS, these treatments do not impede the 
clinical progression of patients that have advanced to SPMS (La Mantia et al., 2012). Moreover, 
clinical efficacy is reduced in patients who develop neutralizing antibody (NAb) responses against 
the treatment (Rog et al., 2006).  
Recent therapeutic strategies have shifted toward monoclonal antibody-based therapies 
(mAbs) that target specific surface proteins to modulate the peripheral immune response 
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(Fontoura, 2010). For example, the United States Food & Drug Administration (FDA) approved 
ocrelizumab (also known as Ocrevus), which is a humanized monoclonal antibody that targets the 
CD20 domain on the surface of B cells for the treatment of RRMS and PPMS (Greenfield et al., 
2018). Two clinical trials, termed OPERA I and OPERA II, demonstrated reduced annual relapse 
rates in individuals suffering from RRMS following treatment with ocrelizumab compared to 
treatment with interferon β-1a (Hauser et al., 2017; Greenfield et al., 2018; Syed, 2018). An 
additional trial, termed ORATORIO, followed patients with PPMS for ≥120 weeks following 
intravenous injection of ocrelizumab or placebo every 24 weeks. The primary clinical endpoint for 
this trial was a diagnosis of disability progression. Ocrelizumab led to reduced disability 
progression compared to the placebo treatment (Montalban et al., 2017). In addition, interferon-
based therapy requires multiple courses of treatment per month whereas ocrelizumab is 
administered one time over a six month period thus reducing the burden upon patients to 
maintain a consistent treatment regimen (Syed et al., 2018). Clinical trials for ocrelizumab were 
specifically designed to include individuals diagnosed with RRMS and PPMS and did not examine 
the effect upon patients with SPMS. Therefore, it is unclear how ocrelizumab affects mechanisms 
associated with later stage neurodegeneration associated with SPMS.   
 
Role of oxidative injury in multiple sclerosis pathogenesis 
Reactive oxygen and nitrogen species (ROS, RNS) are compounds generated as 
byproducts of normal cellular metabolism and include superoxide, hydroxyl radical, peroxide, and 
dioxygen. Under conditions of cellular homeostasis, reactive oxidants are generated in a 
controlled fashion and serve as key signaling molecules for a diverse array of physiological 
processes including cell growth, immunity, inflammation, and autophagy (Finkel et al., 2011). 
Oxidative stress occurs when environmental insults or disease states allow uncontrolled 
production of these molecules which promotes damage to proteins and lipids thereby impairing 
function and accelerating their degradation.  
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Accumulating evidence points to oxidative stress as an important contributor in both the 
early stages of MS progression and later stage chronic neurodegeneration (Qi et al., 2006) 
(Figure 2.2). Oxidative injury in RRMS is primarily associated with inflammatory processes driven 
by activated microglia and macrophages as these cells are considered critical reservoirs of 
reactive oxygen and nitrogen species. Specifically, the cells exhibit a process known as oxidative 
burst which involves the release of pro-inflammatory cytokines and ROS/RNS in response to a 
foreign antigens typically associated with infectious agents (Dendrou et al., 2015). High 
concentrations of ROS/RNS promote damage and destruction of neighboring axons, neurons, 
and oligodendrocytes. 
(Lassmann et al., 2016). 
Neurons are particularly 
susceptible to oxidative 
insults because they are 
quiescent cell types and 
cannot dilute these 
cytotoxic components 
with successive cell 
divisions (Campbell et 
al., 2018). Reactive species can diffuse through the plasma membrane and mediate covalent 
modifications to mitochondrial respiratory chain members and impair ATP production via oxidative 
phosphorylation (Haider, 2015). Moreover, oxidative injury can also induce irreversible mutations 
within mitochondrial DNA thereby disrupting normal gene expression programs and further 
impairing mitochondrial activity. These collective deficits in mitochondrial function, oxidative 
phosphorylation, and subsequent production of ATP mediates a cellular phenotype of energy 
failure leading to neuronal death (Lassmann et al., 2012). In addition to inflammatory 
mechanisms, generation of reactive oxygen species is amplified by the presence of iron liberated 
into the extracellular space through the loss of myelin and oligodendrocytes (Lassmann et al., 
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2012; Haider, 2015). Furthermore, iron is taken up by other cell types within the lesion such as 
microglia and can mediate apoptosis via numerous mechanisms (Dixon et al., 2014). Release of 
iron via cell death mediates a second wave of oxidative damage within the lesion (Lassmann et 
al., 2012; Haider, 2015). Interestingly, ablation of microglia was shown to inhibit the development 
and generation of CNS lesions in the experimental autoimmune encephalomyelitis (EAE) animal 
model of MS further supporting the role of these cells in mediating MS lesion formation and 
pathogenesis (Heppner et al., 2005).    
Clinical studies observed increased byproducts of oxidative damage including 
peroxidized lipids and oxidized glutathione in cerebrospinal fluid (CSF) and plasma of MS 
patients (Hunter et al., 1985; Naidoo et al., 1992). Patient-derived erythrocytes showed reduced 
activity in the antioxidant enzymes, superoxide dismutase and glutathione peroxidase, suggesting 
deficits in cellular ROS defense mechanisms (Zagorski et al., 1991; Karg et al., 1999). In addition, 
isolated mononuclear cells from patients produce higher levels of ROS and nitric oxide compared 
to those from healthy patients supporting their role in promoting disease progression (Sarchielli et 
al., 1997). Importantly, molecular examination of MS lesions in postmortem brain samples 
displayed increased markers of ROS damage corresponding with decreased levels of key 
antioxidants such as glutathione (Langemann et al., 1992). Moreover, these plaques also show 
increased oxidized DNA content compared to control specimens (Vladimirova et al., 1998). 
Collectively, these findings support the contribution of oxidative injury as a conserved mechanism 
throughout disease progression and a potential therapeutic target in MS etiology.  
   
Experimental autoimmune encephalomyelitis 
 Current understanding of MS pathogenesis is largely attributed to studies of experimental 
autoimmune encephalomyelitis (EAE). EAE can be elicited in a variety of species by 
immunization with myelin derived peptides including myelin oligodendrocyte glycoprotein (MOG), 
myelin basic protein (MBP), or myelin proteolipid protein (PLP) emulsified with an adjuvant (Lublin 
et al., 1984). This combination stimulates an autoimmune response similar to that found in MS 
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patients. Furthermore, breakdown of the blood-brain barrier with reagents such as pertussis toxin 
allows infiltration of autoinflammatory cells into the CNS. The phenotype is characterized by 
development of inflammatory and demyelinating lesions within the brain and spinal cord and limb 
paralysis.  In addition, the model exhibits an ocular phenotype paralleling optic neuritis with 
features such as optic nerve thinning, RGC loss, and reduced visual function (Quinn et al., 2011). 
Collectively, this model provides a robust in vivo system to understand neurodegenerative 
processes and testing of novel therapeutic interventions for MS and optic neuritis.  
 Amplification of antioxidant or anti-inflammatory mechanisms has shown therapeutic 
promise in attenuating pathological features of EAE. Several gene therapy strategies have 
successfully ameliorated ocular disease manifestations in EAE animals. AAV2 overexpression of 
ROS scavengers such as superoxide dismutase (SOD2) or catalase reduced features of optic 
nerve pathology including demyelination, optic nerve head swelling, immune infiltration, and RGC 
loss (Guy et al., 1998; Qi et al., 2006; Qi & Lewin et al., 2007; Qi & Sun et al., 2007). Similarly, 
amplifying components involved in mitochondrial function commonly dysregulated in MS 
pathogenesis conferred neuroprotective features. AAV-mediated augmentation of NADH-
dehydrogenase type 2 complex 1 (NDl1) attenuated vision loss, axonal loss, oxidative stress, and 
RGC death in EAE mice (Talla et al., 2013). Gene augmentation of another NADH 
dehydrogenase subunit (NDUFA6) promoted similar neuroprotective effects (Talla et al., 2015). In 
addition, overexpression of mitochondrial heat shock protein 70 (mtHSP70), a chaperone 
involved in mitochondrial protein import and folding, rescued similar disease features as well as 
activities associated with the mitochondrial respiratory chain (Talla et al., 2014). Collectively, 
these investigations support further development of gene-based treatment strategies to prevent 
or reverse MS pathogenesis by amplifying antioxidant pathways or promoting mitochondrial 
function.  
 
Modulation of oxidative metabolism by targeting the NRF2/ARE pathway 
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Nuclear factor (erythroid-derived 2)-like 2 (NRF2) is a basic leucine zipper transcription 
factor that stimulates expression of genes associated with antioxidant defense and cellular 
detoxification. It was originally identified as a DNA binding protein with considerable homology to 
NF-E2 and bound hypersensitive site 2 of 
the β-globin control locus (Moi et al., 
1994). Structurally, NRF2 contains six 
NRF2-ECH homology domains (Neh1-6) 
which participate in DNA binding, nuclear 
localization, and regulation (Figure 2.3A). 
Neh2 contains critical functional motifs that 
are critical for negative regulation of 
protein activity (Katoh et al., 2005). Neh3 
contains a conserved sequence among 
bZIP transcription factors that is essential 
for stimulation of genes containing 
antioxidant response elements (AREs) 
(Nioi et al., 2005). Neh4 and Neh5 function 
as additional transactivation domains by binding the cAMP responsive element binding protein 
(CBP), a conserved co-factor for many transcription factors (Katoh et al., 2001; Abed et al., 
2015).  
In the absence of an oxidative insult, NRF2 is translated and associates with its 
cytoplasmic scaffold Kelch-like ECH-associated protein 1 (KEAP1). This interaction sequesters 
NRF2 within the cytoplasm and prevents it from entering the nucleus (Itoh et al., 1999; Ito et al., 
2003). In this scenario, NRF2 is eventually targeted for proteasomal-mediated degradation 
(McMahon et al., 2003). Upon oxidative challenge, critical cysteine residues within KEAP1 
become modified by rising oxidant and electrophile concentrations thereby altering its 
conformation and facilitating dissociation from NRF2. Under such circumstances, newly 
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synthesized NRF2 freely translocates into the nucleus where it recognizes and binds antioxidant 
response elements (ARE) in upstream regulatory sequences of genes with antioxidant or 
detoxification value including heme oxygenase 1 (HMOX1), NADPH quinone oxidoreductase 1 
(NQO1), and glutathione S transferases (GSTs) (Dinkova-Kostova et al., 2002; Dinkova-Kostova 
et al., 2015) (Figure 2.3B). Moreover, NRF2 contributes a critical role in mitochondrial biogenesis 
and function, and Nrf2 knockout cells exhibit mitochondrial deficits (Dinkova-Kostova et al., 2015; 
Kovac et al., 2015). Transgenic ablation of NRF2 during EAE development generates a 
phenotype of accelerated demyelination, immune cell infiltration, and pro-inflammatory cytokine 
signaling compared to the phenotype in wild-type animals also subjected to EAE (Johnson et al., 
2010). In addition, Nrf2 knockout mice demonstrate enhanced decline in visual function, loss of 
RGCs, and exacerbated optic nerve atrophy (Larabee et al., 2016).  
Accumulating evidence supports therapeutic modulation of NRF2 activity via 
pharmacological approaches or transgenic overexpression in neurodegenerative disease states 
driven by oxidation (Johnson et al., 
2015). EAE mice treated with the 
NRF2 inducer, TFM-735, 
demonstrated reduced disease 
severity and inflammatory cytokine 
production (Higashi et al., 2017). 
Similarly, administration of 
melatonin ameliorated EAE 
pathophysiology that was 
associated with activation of the 
NRF2/ARE pathway (Long et al., 
2018). Several investigations have also interrogated the possibility of NRF2-mediated 
neuroprotection with gene therapy approaches. Xiong et al. (2015) developed a gene 
augmentation strategy that promoted survival and function of cone photoreceptors in pre-clinical 
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models of retinitis pigmentosa. In addition, this study demonstrated a transient increase in 
survival of RGCs targeted with NRF2 expression vectors following optic nerve crush (Figure 2.4). 
Liang et al. (2017) explored a similar approach within mouse models of retinal degeneration 
induced by light damage. Based on the collective data, we hypothesized that stimulation of NRF2 
activity may provide an effective means to protect RGCs in experimental optic neuritis.  
  
Role of SIRT1 in multiple sclerosis and optic neuritis 
Sirtuins are a class of enzymes that regulate numerous cellular processes associated 
with aging, metabolism, stress response, and DNA repair. Seven members comprise the 
mammalian sirtuin family, and each share a conserved catalytic core domain responsible for 
carrying out various protein modifications such as deacetylation (Figure 2.5). Sirtuins are largely 
classified based upon their protein domains 
flanking this enzymatic core, which dictate 
features such as substrate specificity and 
compartmental localization (Michan et al., 
2007). The mammalian homologue of Sir2, 
Sirtuin 1 (SIRT1), is the most well 
characterized family member and an 
evolutionarily conserved NAD+-dependent 
deacetylase that regulates various 
components of cellular metabolism with 
respect to aging, DNA repair, mitochondrial 
biogenesis, and apoptosis (Martin et al., 2015). SIRT1 inhibits apoptosis by direct deacetylation of 
p53 thereby inactivating its cell death signaling cascade (Luo et al., 2001; Vaziri et al., 2001). 
SIRT1 has been shown to enhance DNA damage repair by forming a complex and deacetylating 
Ku70, which is a critical mediator for resolving double-stranded DNA breaks (Jeong et al., 2007). 
Moreover, SIRT1 improves mitochondrial function by enhancing gene expression and direct 
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activation of PGC-1α, an essential transcriptional regulator of mitochondrial-associated and 
antioxidant genes (Amat et al., 2009; Nemoto et al., 2005).    
Several lines of evidence suggest modulating SIRT1 activity via pharmacological 
induction or transgenic overexpression may promote therapeutic outcomes in neurodegenerative 
disease (Fonseca-Kelly et al., 2012; Jeong et al., 2011; Kahn et al., 2012; Khan et al., 2014; Kim 
et al., 2007; Martin et al., 2015; Nimmagadda et al., 2013; Shindler et al., 2007; Shindler et al., 
2010; Zuo et al., 2013). Neuron-specific deletion of SIRT1 exacerbates the CNS phenotype in a 
mouse model of Huntington’s disease 
while transgenic overexpression 
increases survival and rescues 
neurodegeneration in this model (Jeong 
et al., 2011). Similarly, pharmacological 
induction with the known SIRT1 
activator, resveratrol, or lentivirus-
mediated overexpression of SIRT1 in 
the hippocampus promoted 
neuroprotection in a mouse model of 
Alzheimer’s disease/tauopathies (Kim 
et al., 2007). In experimental optic 
neuritis, pharmacologic activators of 
SIRT1, including resveratrol and 
structurally similar polyphenolic compounds, are effective in sustaining RGC survival in EAE 
(Shindler et al., 2007; Shindler et al., 2010). Prophylactic or reactive administration of SIRT1 
activators including SRT501 and SRT647 attenuated RGC loss in EAE. Moreover, administration 
of sirtinol, a well characterized SIRT1 inhibitor, effectively blocked the therapeutic effects of 
SRT501 and SRT647 further emphasizing the neuroprotective role of SIRT1 in EAE pathogenesis 
(Shindler et al., 2007). In addition to pharmacological inducers, Nimmagadda et al. (2013) 
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demonstrated reduced inflammation and demyelination following EAE sensitization in a 
transgenic mouse harboring a neural-restricted SIRT1 overexpression cassette. This investigation 
specifically examined MS lesions localized to the spinal cord and did not interrogate the 
contribution of SIRT1 overexpression in ameliorating ocular disease manifestations (Figure 2.6). 
Based upon the collective evidence supporting the neuroprotective role of SIRT1 in MS 
pathogenesis, I sought to explore the therapeutic potential of SIRT1 gene transfer within RGCs 
during EAE. 
Results 
Design and characterization of first generation RGC neuroprotection vectors 
 
I designed AAV expression cassettes that allow ubiquitous expression of eGFP, human 
NRF2, or human SIRT1 (Figure 2.7A). Proviral expression cassettes were packaged into the 
AAV2 capsid by the CAROT research vector core. These vectors display exceptionally robust in 
vitro activity as shown with RT-qPCR and immunofluorescent analysis. Infection with AAV2.NRF2 
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and AAV2.SIRT1 yielded a several hundred-fold increase in Nrf2 and Sirt1 mRNA compared to 
levels found in non-transduced cells (Figure 2.7B-C). At the protein level, both vectors display 
robust nuclear and cytoplasmic distribution following transduction in ARPE-19 cells (Figure 2.7D-
G). I examined the retinal transduction profile of AAV2 following intravitreal administration of the 
AAV2 vector expressing eGFP in a cohort of wild-type mice. Similar to previously described 
reports, AAV2.eGFP displayed transduction of the ganglion cell layer and optic nerve head 
(Figure 2.8A-B). This vector achieved approximately 21% RGC transduction. RGC transduction 
was quantified by counting the number of eGFP positive RGCs co-labeled with Brn3a antibody 
(Figure 2.8C). I also assessed the activity of AAV2.NRF2 and AAV2.SIRT1 vectors in the murine 
retina by immunolabeling retinal cross-sections with antibodies targeting the 3xFLAG epitope tag 
on each vector. Immunofluorescent analysis revealed FLAG positive labeling of several cells in 
the ganglion cell layer and sparse labeling of cell types localized to the inner nuclear layer 
(Figure 2.8D-F). 
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AAV2.SIRT1 gene transfer preserves visual acuity during EAE 
Animals received bilateral injections of AAV vectors or empty buffer alone. Animals were 
induced with EAE at eight weeks of age by immunization with myelin oligodendrocyte 
glycoprotein (MOG) and complete freunds adjuvant (CFA). This experiment included a cohort of 
control animals which did not develop the EAE phenotype as they received immunizations with 
phosphate buffered saline (PBS) and CFA. Clinical 
features of EAE appeared approximately twelve 
days post-immunization, while sham-induced 
control animals exhibited a completely healthy 
phenotype throughout the experimental timeline 
(Figure 2.9). Visual acuity was assessed with 
optokinetic response (OKR) recordings prior to 
EAE induction and once per week following 
immunization (Figure 2.10). All treatment groups exhibited robust OKR scores prior to EAE 
immunization suggesting vector delivery and transgene expression had negligible impact upon 
visual function. Visual decline was observed approximately 14 days post-immunization. Animals 
treated with AAV2.SIRT1 display a trending increase in OKR compared to control treatments 
throughout the experimental timeline. There was statistically significant preservation at day 35 
(AAV2.SIRT1=0.292 ± 0.016; AAV2.eGFP=0.19 ± 0.035; P=0.032) and day 42 
(AAV2.SIRT1=0.274 ± 0.022; AAV2.eGFP=0.161 ± 0.029; P=0.049) compared with the 
AAV2.eGFP control group. This finding supports the neuroprotective potential of SIRT1 gene 
transfer in preserving visual function in optic neuritis. NRF2 gene augmentation was unable to 
prevent visual decline in EAE mice.  
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AAV2.NRF2 promotes RGC survival in EAE 
 Visual decline in EAE mice corresponds with the loss of RGCs. To investigate the effect 
of anti-oxidant gene augmentation on RGC survival, I isolated retinas from each treatment group 
and immunolabeled them with antibodies directed against the canonical RGC marker, Brn3a 
(Figure 2.11). Reporter vector injected control (non-EAE) eyes displayed RGC numbers 
comparative to those that received sham intravitreal injections suggesting the AAV2 capsid and 
associated dose were well tolerated. RGC numbers were significantly reduced in all treatment 
groups subjected to EAE immunization compared to the non-induced controls (P<0.01). Eyes 
treated with AAV2.SIRT1 demonstrated non-significant but upward trend in RGC survival 
compared to EAE-induced controls. Surprisingly, AAV2.NRF2, while it did not promote functional 
retention, was able to significantly improve total RGC survival compared to what was measured in 
EAE-induced eyes treated with vehicle (P=0.027) (Figure 2.11B). In addition to counting total 
 
33 
RGCs per retina, I also examined the effects of gene transfer on regional density of RGCs 
(central, mid-peripheral, peripheral). NRF2 gene transfer increased the survival of RGCs located 
within peripheral regions of the retina compared to vehicle (P=0.001) and AAV2.eGFP (P=0.002) 
control groups sensitized to EAE (Figure 2.11C). SIRT1 gene therapy mediated a non-significant 
but trending increase in regional survival of RGCs.  
Gene therapy with NRF2 and SIRT1 fails to attenuate optic nerve pathology 
 EAE animals display progressive thinning, demyelination, axonal loss, and cellular 
infiltration of the optic nerve. Thus, I examined the effect of NRF2 or SIRT1 gene therapy on 
features of optic nerve pathology. Optic nerve sections were processed with H&E staining to label 
immune cell infiltrates. Non-EAE samples displayed minimal evidence of immune infiltration. 
However, all treatment groups subjected to EAE immunization showed enhanced evidence of 
cellular infiltrates. Moreover, neither NRF2 nor SIRT1 gene augmentation was able to attenuate 
this feature (Figure 2.12A). To examine the effect of gene transfer on demyelinaton, optic nerves 
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were stained with luxol fast blue (LFB). Optic nerve sections derived from healthy control animals 
showed robust staining of myelin supporting absence of the disease phenotype. All treatment 
groups subjected to EAE displayed a reduction in myelination. Likewise, treatment with 
AAV2.NRF2 or AAV2.SIRT1 did not preserve the myelin coating compared to controls (Figure 
2.12B). 
 
 
 
 
 
 
 
 
Optimization of RGC-specific gene transfer 
While we were able to observe some evidence of retinal neuroprotection with NRF2 or 
SIRT1 gene therapy, these effects were particularly small and did not successfully ameliorate all 
aspects of ocular EAE pathogenesis. One potential approach to enhancing this therapeutic 
response in the future is to increase transduction efficiency as this is only 21% using the AAV2 
vector. Various methods incorporating rational design or in vivo selection have generated novel 
AAV capsids with improved potency and tropism for retinal cell types compared to naturally 
isolated serotypes such as AAV2. While AAV7m8 does enhance RGC gene transfer, its activity is 
not specific to the ganglion cell layer. In fact, this capsid was initially developed to bypass the 
GCL and inner retina to reach cell types occupying the ONL including photoreceptors and RPE 
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when coupled with a less surgically invasive intravitreal injection. Recently, Chaffiol et al. (2017) 
identified a minimal promoter sequence from the human gamma synuclein (SNCG) gene that 
drives robust and specific transgene expression within RGCs (Figure 2.13). I adapted this 
promoter to an AAV expression cassette encoding a reporter gene, and packaged it into the 
AAV7m8 capsid. I hypothesized that the 
AAV7m8 capsid would provide greater 
transduction of RGCs than AAV2. In addition, 
coupling this capsid with the SNCG promoter 
would restrict gene expression to the RGC layer. 
Wild-type animals received intravitreal injection 
of AAV7m8.SNCG.eGFP.WPRE (1x1010 vg) and 
histology was evaluated four weeks later. The 
AAV7m8 vector provided potent transduction of 
the ganglion cell layer (GCL). Transgene 
expression was observed mostly to the GCL with 
slight off target expression observed in the inner retina, suggesting this promoter is not truly an 
“RGC specific” regulatory element. Nonetheless, off target transgene expression was not 
observed in cell types of the outer nuclear layer (Figure 2.14B). Next, I generated an additional 
SNCG-driven AAV vector encoding the SIRT1 transgene. Unlike the previously described 
construct based on AAV2, this vector contains a codon-optimized human SIRT1 sequence 
(copt.SIRT1) and terminates into a woodchuck hepatitis posttranscriptional regulatory element 
(WPRE) followed by the bovine growth hormone (bGH) polyadenylation signal (Figure 2.14A). 
Vectors were generated and tested in the mouse retina following intraviteal delivery at a 1x1010 
vg dose. Since the copt.SIRT1 sequence did not contain an epitope tag, retinal sections were 
stained with antibodies directed against SIRT1 protein. Fluorescent microscopy revealed 
enhanced SIRT1 expression within the GCL, suggesting potent expression of the SNCG-driven 
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vector (Figure 2.14B). The therapeutic utility of this vector is currently being tested within the 
EAE mouse model.  
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Materials and methods 
Animals  
C57Bl/6J mice were obtained from the Jackson Laboratory and raised in a 12-hour 
light/dark cycle. Animals were housed at the University of Pennsylvania vivarium in compliance 
with ARVO guidelines on the care and use of laboratory animals as well as with institutional and 
federal regulations. 
First generation AAV vector design and production 
Human SIRT1 (transcript variant 1) and human NRF2 (transcript variant 1) cDNA clones 
were obtained from Origene. Sequences were amplified with Q5 DNA polymerase (NEB) and 
cloned into an AAV expression plasmid using the In-Fusion HD cloning kit (Clonetech). 
Transgene expression was driven by the CAG promoter cassette derived from pDRIVE-CAG 
(Invivogen). Both cDNA sequences contained a C-terminal 3xFLAG epitope tag that terminates 
into a bovine growth hormone (bGH) polyadenylation sequence. AAV expression cassettes were 
flanked by the AAV2 inverted terminal repeats. A proviral plasmid driving expression of enhanced 
green fluorescent protein (eGFP) was obtained from Dr. Jean Bennett (University of 
Pennsylvania) and contains identical cis regulatory elements. AAV2.NRF2, AAV2.SIRT1, and 
AAV2.eGFP vectors were generated using previously described methods and purified with CsCl 
gradient centrifugation by the CAROT research vector core at the University of Pennsylvania2. 
RGC-specific AAV vector design and production 
The human SNCG promoter sequence was obtained from Chaffiol et al. (2017) and 
synthesized by DNA2.0/ATUM. This sequence was cloned into an AAV proviral plasmid 
containing the enhanced green fluorescent protein cDNA sequence terminating into a woodchuck 
hepatitis virus posttranscriptional regulatory element (WPRE) and bovine growth hormone (bGH) 
polyadenylation signal. The human SIRT1 cDNA sequence was codon optimized and synthesized 
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by DNA2.0/ATUM. The sequence was cloned into the SNCG-driven AAV proviral backbone 
plasmid with the In-Fusion HD cloning system. AAV7m8.SNCG.eGFP.WPRE and 
AAV7m8.SNCG.copt.SIRT1.WPRE vectors were generated by the CAROT research vector core.  
Cell culture 
ARPE-19 cells were supplied by ATCC (Manassas, VA, USA) and grown at 37oC with 5% 
CO2. Cells were maintained in Dulbecco’s modified eagle medium: nutrient mixture F-12 
(DMEM/F12; Gibco) and supplemented with 10% fetal bovine serum (FBS) and 1% penicillin-
streptomycin. 84-31 cells were provided by Dr. James Wilson (University of Pennsylvania) and 
were cultured in DMEM-GlutaMax (Gibco) and supplemented with 10% FBS and 1% penicillin-
streptomycin. 84-31 cells were seeded at a density of 350,000 cells and transduced with AAV2 
vectors at an MOI of 100,000. Cells were harvested for expression analysis at 48 hours post-
transduction. For AAV transduction in ARPE-19 cells, 150,000 cells were plated and transduced 
with AAV2 vectors at an MOI of 100,000. Cells were harvested for expression analysis at 72 
hours post-transduction. Cells were rinsed with PBS and fixed in 4% paraformaldehyde for fifteen 
minutes at room temperature. Afterwards, cells were blocked in 0.1% Triton X-100 and 1% bovine 
serum albumin (BSA) for 30 minutes at room temperature. Cells were incubated with primary 
antibody solution containing 1%BSA and rabbit anti-FLAG antibody (CST #14793; 1:200) for 1 
hour at room temperature. Cells were washed with PBS and incubated in secondary antibody 
solution containing 1%BSA and goat anti-rabbit Alexa Fluor-594 antibodies (1:500) for 1 hour at 
room temperature. Cells were removed from secondary incubation, washed in PBS, and mounted 
with Fluoromount-G (Southern Biotech) containing DAPI.   
Quantitative real-time PCR (RT-qPCR) 
RNA was isolated from 84-31 cells (provided by Dr. James Wilson) using the Macherey-
Nagel Nucleospin RNA kit. First-strand cDNA synthesis was performed using 500 ng of total RNA 
with the SuperScript III first-strand synthesis system according to manufacturer’s protocol. Real-
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time PCR was performed with the Applied Biosystems 7500 Fast system using the Power SYBR 
green PCR master mix (Invitrogen). The following primer sequences were used: 5’ 
CCACTCCTCCACCTTTGAC 3’ (human GAPDH Forward), 5’ ACCCTGTTGCTGTAGCCA 3’ 
(human GAPDH Reverse), GAGCTGGGGTGTCTGTTTCA (human SIRT1 Forward), 
GGAAGTCTACAGCAAGGCGA (human SIRT1 Reverse), GTCACATCGAGAGCCCAGTC 
(human NRF2 Forward), and AGCTCCTCCCAAACTTGCTC (human NRF2 Reverse). Relative 
gene expression was quantified with the ΔΔCT method and normalized to GAPDH. 
Intravitreal injections 
Four week old mice were anesthetized by isoflurane inhalation. A 33 ½ gauge needle 
was used to create a small incision at the limbus. Afterwards, a ten microliter Hamilton syringe 
(701 RN, Hamilton Company, Reno, NV, USA) attached to a 33 gauge blunt-end needle was 
inserted into the vitreous cavity with the needle tip placed directly above the optic nerve head. 1-2 
microliters of AAV preparation were dispensed into each eye bilaterally.  
Induction and score of EAE 
Eight week old C57Bl/6 mice were anesthetized by isoflurane inhalation and injected at 
two sites subcutaneously with 200 micrograms of myelin oligodendrocyte glycoprotein peptide 
(MOG35-55, Genscript, Piscataway, NJ, USA) emulsified in Complete Freund’s Adjuvant (CFA; 
Difco, Detroit, MI, USA) with 2.5 mg/mL mycobacterium tuberculosis (Difco). Control mice that 
were not induced for EAE were injected with an equal volume of PBS and CFA. All mice were 
given 200 ng pertussis toxin (List Biological, Campbell, CA, USA) in 0.1 milliliters of PBS by 
intraperitoneal injection at 0 hours and 48 hours post-immunization with MOG35-55. Clinical EAE 
was assessed using a previously described five-point scale19: no disease = 0, partial tail paralysis 
= 0.5, tail paralysis or waddling gait = 1.0, partial tail paralysis and waddling gait = 1.5, tail 
paralysis and waddling gait = 2.0, partial limb paralysis = 2.5, paralysis of one limb = 3.0, 
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paralysis of one limb and partial paralysis of another = 3.5, paralysis of two limbs = 4.0, moribund 
state = 4.5, death = 5.0.  
Optokinetic response recordings 
Visual function was assessed by measuring the optokinetic response (OKR) using the 
OptoMotry software and apparatus (Cerebral Mechanics, Inc, Medicine Hat, AB, Canada) as 
previously described (Prusky et al., 2004; McDougald et al., 2018). OKR was determined as the 
highest spatial frequency where mice track a 100% contract grating that is projected at different 
spatial frequencies. Measurements were performed by an investigator masked to the 
experimental treatments. 
Retinal histology and RGC quantification 
Eyes were harvested and placed in 4% paraformaldehyde (PFA) in phosphate buffered 
saline (PBS) overnight at 4 degrees celsius. Eyes were washed in PBS followed by dissection of 
retinal cups. Tissues were permeabilized and blocked in 2% Triton X-100, 10% normal donkey 
serum, and PBS and then incubated with goat anti-Brn3a antibody (Santa Cruz Biotechnology, 
Dallas, TX, USA) diluted 1:100 at 4oC. Retinal cups were washed and then incubated in 
secondary antibody solution containing 2% Triton X-100, 10% normal donkey serum, and donkey 
anti-goat Alexa Fluor 594 antibody (1:500 dilution). After washing, samples were prepared as 
flatmounts and mounted onto glass slides with Fluoromount-G (Southern Biotech) containing 4',6-
diamidino-2-phenylindole (DAPI). RGCs were quantified as previously described7,19,25,26. Briefly, 
retinal micrographs were recorded at 40X magnification in 12 standard fields (1/6, 3/6, and 5/6 of 
the retinal radius from the center of the retina in each quadrant). Total RGC counts from the 12 
fields per retinal sample covering a total area of 0.45mm2/retina were recorded by an investigator 
masked to the experimental conditions using the ImageJ software. Retinal cross-sections were 
incubated in blocking buffer containing PBS, 2% Triton X-100, and 10% normal donkey serum for 
1 hour at room temperature. Next, sections were incubated in primary antibody solution 
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containing the previously described components and a rabbit anti-FLAG antibody (CST #14793) 
at 1:100 dilution overnight in a humidified chamber at room temperature. Sections were washed 
in PBS three times and incubated in secondary antibody solution containing donkey anti-rabbit 
Alexa Fluor 488 antibody diluted at 1:200 for two hours at room temperature. Slides were then 
washed in PBS three times and mounted with Fluoromount-G containing DAPI.  
Optic nerve histology and scoring 
Histologic staining and scoring was performed as in prior studies. Optic nerves were 
harvested, fixed in 4% PFA, and embedded in paraffin. Nerves were subsequently cut into 5 μm 
longitudinal sections. To examine immune cell infiltration, sections were stained with hematoxylin 
and eosin (H&E). Inflammation was scored by an investigator blinded to the experimental 
treatments, and nerves were graded on a 0-4 point scale: no infiltration = 0, mild cellular 
infiltration = 1, moderate infiltration = 2, severe infiltration = 3, massive infiltration = 4. Sections 
were stained with luxol fast blue (LFB) to assess myelination. These sections were graded on a 
0-3 point scale:  0 = no demyelination; 1 = scattered foci of demyelination; 2 = prominent foci of 
demyelination; and 3 = large (confluent) areas of demyelination. 
Statistics 
All data are represented as means ± SEM. Differences between treatment groups with 
respect to OKR responses, RGC quantification, and optic nerve histopathology were compared 
using a one-way ANOVA followed by Turkey’s honest significant difference test using GraphPad 
Prism 7.0. Differences were considered statistically significant at P < 0.05. 
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CHAPTER 3 Metabolic reprogramming of photoreceptors in retinitis pigmentosa 
 
Retinitis pigmentosa: clinical phenotype, genetics, and treatment 
 Retinitis pigmentosa (RP) comprises a heterogenous group of photoreceptor 
degenerative diseases associated with a peripheral-to-central mode of vision loss. The earliest 
pathological hallmark includes deficits in dim light vision typically beginning in the second decade 
of life. Loss of night vision is followed by decreased visual fields and advancing tunnel vision. 
Central vision associated with daylight, 
color, and high acuity vision 
deteriorates in later stage disease via 
the secondary degeneration of cone 
photoreceptors culminating in a 
condition of complete blindness by 40-
50 years of age (Hartong et al., 2006). 
Clinical hallmarks can be identified 
with a fundoscopic evaluation and 
include abnormal coloration of the 
optic disc, bony spicule pigmentation, 
and narrowing of the retinal blood 
vessels (O’neal et al., 2018) (Figure 
3.1). Approximately 1 in 3000-7000 
individuals are affected by retinitis pigmentosa on a global scale (Ferrari et al., 2011). Mutations 
in over 60 known genes are responsible for onset of clinical disease (Figure 3.2). Defects in 
these genes may be associated with structural deficits and/or a variety of unique cellular functions 
and pathways including photo-transduction, ciliary transport, or protein trafficking. Pathogenic 
mutations can be transmitted via autosomal recessive (50-60%), dominant (30-40%), or X-linked 
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(5-15%) inheritance patterns (Hartong et al., 2006). Mutations in the rod phototransduction 
pigment rhodopsin (RHO) account for 20-30 percent of all autosomal dominant forms of RP 
(Hartong et al., 2006; Ferrari et al., 2011). The vast genetic heterogeneity of this disease is also 
met with extensive clinical variation. Mutations within the same gene may confer vastly different 
clinical outcomes. Many of these genes listed in Figure 3.2 are also associated with other forms 
of inherited retinal degeneration including juvenile macular degeneration (ABCA4), cone-rod 
dystrophy (CRX), and Leber’s congenital amaurosis (CRB1, RPE65). In addition, defects in many 
of these genes may also present with extra-ocular clinical symptoms. For example, approximately 
20-40% of recessive diseases are associated with Usher’s syndrome, which is characterized by 
retinitis pigmentosa and severe hearing loss due to dysfunction and death of mechanosensory 
hair cells of the inner ear (Boughman et al., 1984). Bardet-Biedl syndrome (BBS) is a 
multisystemic, neurodevelopmental disease that may present with retinitis pigmentosa, renal 
complications, polydactyly, obesity, and cognitive impairment (Weihbrecht et al., 2017). Finally, 
some RP subtypes manifest via incomplete penetrance further complicating genotype-phenotype 
correlations (Ferrar et al., 2011).  
There are currently no approved 
treatments to effectively halt or reverse vision 
loss in RP. Several studies interrogated the 
effects of dietary supplements in delaying 
visual decline (Berson et al., 1993; Massof et 
al., 1993). A randomized trial investigated the 
protective value of oral vitamin A and/or E in 
601 patients aged 18 to 49 suffering from 
various RP subtypes. Patients that received 
high dose vitamin A treatment displayed a 
significantly slower yet modest decline in cone 
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ERG amplitudes compared to other groups (Berson et al., 1993). However, other outcome 
measures of visual function including visual field area and visual acuity did not differ between 
groups in this initial study. Moreover, a recent review of this evidence concluded there is no 
significant benefit of vitamin A supplementation in impeding disease progression (Rayapudi et al., 
2013). Therapeutic strategies currently in development are centered around gene and cell-based 
treatment platforms. The clinical success and recent FDA and anticipated European Medicines 
Agency approval of Luxturna provides a framework for the downstream development of gene 
replacement therapies for other forms of IRD. However, developing a gene therapeutic tailored to 
each specific RP subtype is met with extensive challenges, as described below.  
Challenges of gene replacement therapy for retinitis pigmentosa 
 Although many RP subtypes may be amenable to gene replacement, several challenges 
impede development of a treatment for all disease manifestations. Foremost, RP is an incredibly 
genetically heterogeneous collection of diseases. Pathological mutations may be inherited via an 
autosomal recessive, dominant, or X-linked fashion (Hartong et al., 2006) (Figure 3.2). Therefore, 
gene augmentation may not be a suitable therapeutic approach for dominant mutations, which in 
most cases, will require alternative strategies to silence the mutant allele. Moreover, many RP-
associated disease genes contain coding sequences that exceed the approximately five kilobase 
DNA packaging capacity of conventional AAV vectors. However, other vector platforms that can 
accommodate larger DNA sequences contain significant drawbacks including unstable gene 
expression patterns, insufficient tropism for photoreceptors and other retinal cell types, 
heightened immunogenicity, and potential for insertional mutagenesis in the case of integrating 
vectors (Thomas et al., 2003). Finally, many clinical cases remain undiagnosed with respect to 
the underlying genetic aberration, further complicating the course of action for therapeutic 
intervention.  
Conserved mechanisms of photoreceptor degeneration in RP 
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The early onset and loss of rod-mediated visual function is characterized by deficits in 
genes associated with rod photo-transduction and homeostasis, providing a direct explanation for 
the loss of this photoreceptor subtype. Interestingly, cone photoreceptors which degenerate in 
later stage disease are typically unaffected by many of these pathogenic mutations. This 
secondary degenerative event has led to extensive exploration of potential conserved 
neurodegenerative mechanisms discussed in detail below. Various treatment strategies in 
development aim to preserve retinal function at various therapeutic “windows of rescue” based on 
the patient’s stage of degeneration (Figure 3.3) 
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Oxidative injury  
Oxidative stress is implicated to play a significant role in RP pathophysiology (Punzo et 
al., 2012; Shen et al., 2005). The major hypothesis to support this mechanism involves 
dysregulated oxygen consumption and redox imbalance in the retina following rod death. Rods 
comprise >90% of the photoreceptor population and consume the vast majority of oxygen 
delivered to the outer retina via the choroid. 
Following rod clearance, the remaining cone 
cells are exposed to an aberrant increase in 
oxygen levels as the choroid cannot 
autoregulate the output of oxygen transport to 
the retina. This hyperoxic environment leads 
to the generation of ROS within the retina 
thereby promoting oxidative damage to 
proteins, lipids, and DNA. Cones may be 
particularly vulnerable to changes in oxygen 
content as they contain 2-10 times more 
mitochondria, which provide an endogenous 
source of ROS production via mitochondrial 
respiration, as rod photoreceptors (Hoang et 
al., 2002; Perkins et al., 2003). Various lines 
of evidence from animal models and patients 
support the role of oxygen toxicity in RP pathogenesis. Canonical markers of oxidative stress 
such as acrolein, 4-hydroxynonenal (HNE), nitrotyrosine, and 8-hydroxy-2’-deoxyguanosine (8-
OHdG) are elevated in various animal models of RP (Shen et al., 2005; Trachsel-Moncho et al., 
2018; Xiong et al., 2015). Peripheral blood from RP patients revealed heightened levels of lipid 
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peroxidation and other markers of oxidative stress compared to healthy controls. In addition, 
aqueous humor isolated from these patients also demonstrated reduced superoxide dismutase 
activity and protein concentration (Martinez-Fernandez de la Camara et al., 2013). Administration 
of pharmacological reagents with antioxidant properties has shown therapeutic efficacy in slowing 
photoreceptor degeneration in RP models (Komeima et al., 2006; Komeima et al., 2007). Gene 
augmentation approaches utilizing antioxidant proteins have been shown to slow the course of 
photoreceptor degeneration in RP models. Overexpression of ROS scavenging enzymes, such 
as SOD2 or catalase, slowed the course of cone degeneration in RP models (Lu et al., 2009; 
Usui et al., 2009). Xiong et al. (2015) demonstrated increased cone survival, photoreceptor 
structure, functional preservation, and reduced markers of oxidative stress across several RP 
mouse models by overexpressing the antioxidant transcription factor, NRF2. Interestingly, 
overexpression of PGC-1α, another transcription factor with critical functions associated with 
oxidative metabolism and mitochondrial function, exacerbated photoreceptor degeneration in 
these models (Xiong et al., 2015). 
Microglial activation 
Microglial cells (MGCs) are resident macrophages of the nervous system that remain 
quiescent until activated in response to environmental stimuli such as inflammation and tissue 
damage. Once active, they serve two primary functions including phagocytosis of neighboring 
cellular debris and secretion of pro-inflammatory molecules to combat potential infectious agents 
(Saijo et al., 2011). While this response is intended to be protective in nature, chronic MGC 
activation can cause unintended cytotoxicity in the context of many neurodegenerative disease 
states (Cai et al., 2014; Gupta et al., 2003; Lucin et al., 2009; Wang et al., 2013; . Chronic 
microglial activation is found in many ocular diseases including age-related macular degeneration 
and retinitis pigmentosa (Gupta et al., 2003). With respect to RP, a decrease in ONL thickness 
corresponded with increased MGC density and cell numbers consistent between four 
independent mouse strains (Zhang et al., 2018).  Moreover, genetic rescue of rod photoreceptors 
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in related models successfully halted MGC activation, further highlighting the pathologic 
contribution of these cells in RP-associated photoreceptor degeneration (Zhang et al., 2018). 
Furthermore, this evidence also suggests MGC activation as another potential conserved target 
to delay photoreceptor degeneration.   
Loss of rod-mediated trophic signaling support 
Rod-derived cone viability factor (RdCVF) is encoded by the Nxnl1 gene and expressed 
exclusively by rod photoreceptors and bipolar cells in the retina. The pre-mRNA transcript is 
subject to alternative splicing, yielding two protein isoforms with distinct functions. The longer 
isoform (RdCVFL) is restricted to the rod cell body and contains an additional thioredoxin-like fold 
with putative enzymatic function associated with antioxidant capacities (Byrne et al., 2015; 
Elachouri et al., 2015; Mei et al., 2016). The shorter isoform (RdCVFS) is a secreted protein that 
exhibits neurotrophic activity upon neighboring cone cells. Direct protein administration or AAV-
mediated expression of both isoforms have been evaluated in mouse models of RP. In each 
system, the short isoform promotes cone viability despite the emergence of physiological insults 
mediated by rod clearance (Ait-Ali et al., 2015; Byrne et al., 2015). Recent studies identified the 
mechanism by which RdCVFS exhibits this trophic activity. Ait-ali et al. (2015) identified basigin-1 
(BSG1), a transmembrane protein specifically expressed on the surface of photoreceptors, as the 
receptor for RdCVFS. Using a combination of mass spectrometry and fluorescence resonance 
energy transfer, these components were shown to form a complex with glucose transporter 1 
(GLUT1) on the cone surface. GLUT1 is transmembrane protein associated with insulin-
independent, facilitated diffusion of glucose into cells. Interaction between these components 
theoretically induces a conformational change in GLUT1, thereby enhancing glucose transport 
into the cone cell (Ait-Ali et al., 2015). The increased glucose uptake and utilization likely provides 
partial relief from ROS-mediated degeneration and other components of metabolic stress 
observed in secondary cone degeneration, as described below.  
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Nutrient shortage and metabolic stress 
Photoreceptors are among the highest energy consuming cells in the human body 
(Ames, 2000). Similar to other neuronal populations, they require extensive quantities of ATP to 
stabilize membrane potential. Unlike other neurons, photoreceptors are constantly growing and 
recycling a significant portion of their cellular structure. This daily shedding and renewal of the 
outer segment places a substantial energetic and biosynthetic burden upon the cell. Therefore, 
photoreceptors must strike a delicate balance in the utilization of nutrients for oxidative 
phosphorylation to achieve optimal energy production as well as anabolic metabolism to maintain 
outer segment re-synthesis. Photoreceptors utilize a process known as aerobic glycolysis (or the 
Warburg effect) to meet these diverse metabolic demands. Aerobic glycolysis is typically 
observed in highly proliferative cell types, such as cancer cells, and is characterized by the 
conversion of glucose to lactate in the presence of oxygen (Jones et al., 2015). Under these 
circumstances, the photoreceptor can transfer glycolytic intermediates into the pentose 
phosphate pathway to generate precursor molecules for biosynthesis and NADPH, which is an 
important cofactor in other biosynthetic reactions and antioxidant defense (Jiang et al., 2014). 
Petit et al. (2018) investigated the importance of aerobic glycolysis within rod and cone cells 
through cre-mediated depletion of hexokinase 2 (HK2). This enzyme is highly expressed within 
photoreceptors (Ait-Ali et al., 2015) and is responsible for the conversion of glucose to glucose-6-
phosphate as the initial step in glycolysis. Previous investigations suggest HK2 functions as a 
critical “gatekeeper” of aerobic glycolysis (Wolf et al., 2011). Loss of HK2 did not impact the 
overall survival and health of rod cells but impaired their function as demonstrated by a ~30% 
reduction in scotopic a- and b-wave ERG responses compared to control animals. In addition, 
HK2 ablation exacerbated cone death kinetics in the Pde6brd1 mouse of retinitis pigmentosa, thus 
underlining the critical nature of aerobic glycolysis in cone survival (Petit et al., 2018).  
A more recently characterized mechanism of photoreceptor degeneration in RP involves 
metabolic stress stemming from insufficient nutrient uptake. A seminal report by Punzo et al. 
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(2009) investigated changes in cone metabolism following rod loss in a panel of RP mouse 
models varying in their kinetics of photoreceptor degeneration. Irrespective of the mouse strain, 
cones displayed a global switch in metabolic pathways critical to anabolic metabolism toward 
mechanisms associated with catabolism and other recycling pathways. Components associated 
with the insulin/mTOR pathway were particularly downregulated at the onset of cone death. 
Moreover, these transcriptional changes corresponded with an upregulation in features 
associated with starvation-induced mechanisms such as chaperone-mediated autophagy and 
increased expression of glucose transporters and HIF1α. Systemic administration of insulin 
alleviated cone atrophy in a transient manner, suggesting stimulation of the insulin/mTOR 
pathway may provide an effective means to improve cone survival in this disease context (Punzo 
et al., 2009) (Figure 3.5). The exact mechanism by which cones become nutrient deprived is 
unknown. However, it is hypothesized that loss of rod structural support disrupts nutrient flow 
from the RPE to the cone cells thus implementing this phenotype (Punzo et al., 2012).  
 
 
 
 
 
 
 
 
 
The insulin/AKT/mTOR pathway in ocular health and disease 
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The mechanistic target of rapamycin (mTOR) is a serine/threonine kinase that influences 
numerous aspects of cellular metabolism in response to extracellular signaling events, 
intracellular energy status, and nutrient availability. It carries out several functions within two 
distinct complexes. mTOR complex 1 (mTORC1) is composed of five subunits including mTOR, 
RAPTOR, mLST8, PRAS40, and DEPTOR (Saxton et al. 2017). RAPTOR plays a pivotal role in 
the recruitment of target proteins through recognition of TOR signaling (TOS) motifs found within 
downstream substrates (Nojima et al., 2003; Saxton et al., 2017). mLST8 provides structural 
stabilization and 
support to the 
mTOR kinase 
domain allowing it 
to effectively 
phosphorylate 
target proteins 
(Saxton et al., 
2017; Yang et al., 
2013). PRAS40 
and DEPTOR 
promote functions 
inhibitory to 
substrate binding 
and complex 
activation (Sancak et al., 2007; Saxton et al., 2017; Wang et al., 2007; Peterson et al., 2009). 
Once active, mTORC1 phosphorylates a variety of protein targets essential for macromolecular 
synthesis. It enhances protein synthesis through inhibition of eukaryotic translation initiation factor 
4E binding protein 1 (4E-BP1) and activation of S6 kinase 1 (S6K1) (Blommaart et al., 1995; Hara 
et al., 1998). Moreover, mTORC1 also increases lipid biosynthesis through several mechanisms 
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that converge upon activation of sterol regulatory element binding proteins (SREBPs), which are 
transcription factors that control lipogenic gene expression (Bakan et al., 2012). Such processes 
are likely critical for photoreceptor homeostasis as daily shedding and re-synthesis of outer 
segment membranes requires extensive protein and lipid turnover. mTOR complex 2 (mTORC2) 
contains six components including mTOR, mLST8, RICTOR, DEPTOR, Proctor1/2, and mSIN1 
(Saxton et al., 2017). RICTOR serves a comparable role to RAPTOR in recruitment of mTOR 
substrates (Sarbassov et al., 2004). DEPTOR serves a regulatory role by inhibiting kinase activity 
in response to various stimuli. mSIN1 promotes assembly of the complex and mTOR kinase 
activity (Frias et al., 2006). mTORC2 controls processes associated with cell proliferation and 
survival. It phosphorylates various members of the protein kinase C (PKC) family which are 
involved in cytoskeletal remodeling and cell migration (Jacinto et al., 2004; Sarbassov et al., 
2004). In addition, mTORC2 regulates cell survival and proliferation through downstream 
activation of AKT (Saxton et al., 2017). 
Downstream investigations provide a more detailed elucidation of the contribution of 
mTOR in photoreceptor disease and neuroprotection. Venkatesh et al. (2015) utilized a cre-
dependent system to conditionally delete upstream 
suppressors in the mTOR signaling cascade to interrogate 
the effects upon cone metabolism, survival, and function in 
various RP mouse lines (Figure 3.6).  Similarly, Zhang et al. 
(2016) investigated the effects of Tsc1 ablation in the 
Pde6bH620Q/H620Q mouse retina and observed similar 
neuroprotective features corresponding with mTOR 
activation. Interestingly, this investigation described 
beneficial effects upon both cone and rod photoreceptor 
subtypes, suggesting the putative neuroprotective effects of 
mTOR stimulation are not limited to cone photoreceptors in 
RP disease progression. An additional investigation demonstrated enhanced cone survival in the 
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Pde6brd1 mouse retina following electroporation of a plasmid expressing a constitutively active 
mTOR mutant (Rajala et al., 2018) (Figure 3.7). Notably, the mTOR cDNA sequence is 
approximately 7.7 kilobases and thus exceeds the packaging capacity of AAV vectors. Therefore, 
alternative means are necessary to stimulate mTOR activation with clinically relevant vector 
systems.       
Approaches to stimulating mTOR signaling activity with AAV-mediated gene augmentation 
I hypothesized that AAV-mediated delivery and augmentation of critical components 
involved in stimulation of the canonical mTOR signaling cascade could effectively reprogram 
cellular metabolism and refute cone photoreceptor degeneration in pre-clinical models of RP 
(Figure 3.8). Prior investigations highlight the therapeutic potential of reprogramming cell 
metabolism in neurodegenerative disease models by direct stimulation of AKT activity via 
pharmacological induction or gene augmentation (Isiegas et al., 2016; Ries et al., 2006). Ries et 
al. (2006) observed neuroprotective value upon dopaminergic neurons in a mouse model of 
Parkinson’s disease following AAV-mediated augmentation of AKT. Downstream studies 
examined the contribution of AKT overexpression in promoting mTOR activity within retinal cell 
types.  
The AKT family is composed of three isoforms encoded by separate genes including 
AKT1/PKBα, AKT2/PKBβ, and AKT3/PKBγ. Mice deficient in AKT1 display an impaired growth 
phenotype, and animals devoid of AKT2 succumb to metabolic disease associated with insulin 
intolerance (Chen et al., 2001; Cho et al., 2001; Cho & Thorvaldsen et al., 2001) . The role of 
AKT3 has been much more elusive, but various reports suggest this isoform plays a critical role in 
neurodevelopment and neuronal homeostasis. Murine knockouts of AKT3 but not AKT1 or AKT2 
demonstrate reduced brain and neuron size. Furthermore, AKT3 inactivation decreases 
downstream stimulation of mTOR signaling components such as p70 S6 kinase in brain tissues 
suggesting a critical role in controlling this pathway within neurons (Easton et al., 2005). Given 
the collective evidence supporting the role of AKT3 in stimulation of mTOR signaling within 
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neurons, I selected this gene as a candidate to reprogram photoreceptor metabolism in retinitis 
pigmentosa models.  
Ras homolog enriched in brain (Rheb) is a small GTPase associated with various cellular 
activities including protein synthesis, growth, and regeneration. From a mechanistic perspective, 
many of these processes are driven by the 
role of Rheb in stimulating mTOR complex 
1 (mTORC1). When cellular nutrients and 
energy are abundant, mTORC1 is 
recruited to the lysosomal membrane by 
RAPTOR where it interacts with Rheb 
(Groenewoud et al., 2013). The exact 
mechanism in which Rheb activates 
mTORC1 is not fully understand. 
However, evidence suggests GTP-bound 
Rheb induces a conformational change 
within mTORC1 that activates it 
allosterically (Yang et al., 2017). 
Moreover, Rheb demonstrates specific 
activity to mTORC1 and does not 
influence the activation of mTORC2 (Sato et al., 2009). Upstream of this process, Rheb activity is 
predominantly regulated by the tuberous sclerosis complex (TSC1/2). Specifically, tuberin (TSC2) 
functions as a GTPase activating protein (GAP) towards Rheb, thereby stimulating Rheb to 
hydrolyze its GTP cargo to GDP (Inoki et al., 2003). Once bound to GDP, Rheb enters an inactive 
state thereby inhibiting its capacity to stimulate mTORC1.  
Stimulating mTORC1 activity via caRheb overexpression has demonstrated therapeutic 
promise in several neurodegenerative disease models. Reinstating mTORC1 activity via this 
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approach rescues neuropathology and cardiac phenotypes in mouse models of Huntington’s 
disease (Child et al., 2018; Lee et al., 2015). In the context of retinal degenerative disease 
models, Jeong et al. (2015) reported the ability of Rheb gene transfer to upregulate expression of 
ciliary neurotrophic factor (CNTF) and its primary cell-surface receptor (CNTFRα) in 
dopaminergic neurons. Previous studies utilizing AAV-mediated gene augmentation of CNTF 
demonstrate trophic effects in retinal degenerative disease models (Liang & Aleman et al., 2001; 
Liang & Dejneka et al., 2001). Therefore, one could surmise the potential of Rheb augmentation 
to promote photoreceptor neuroprotection via multiple outlets including mTORC1 stimulation and 
the activation of other pro-survival mechanisms such as those mediated by CNTF/CNTFRα. 
Based on this collective data, I hypothesized that Rheb gene augmentation would effectively 
stimulate mTOR activity thereby promoting photoreceptor survival in models of retinitis 
pigmentosa. 
In this study, I investigated the effects of AKT3 or caRheb overexpression in the 
Pde6brd10 mouse model of retinitis pigmentosa. Disease in the Pde6brd10 mouse is similar to that 
in the Pde6brd1 mouse model (Figures 3.5 and 3.7) except that the progression is slightly 
delayed (Chang et al., 2002). It contains a missense mutation in exon 13 of the Pde6b gene that 
generates a premature stop codon. This gene encodes the β subunit of the cGMP 
phosphodiesterase (PDE6) complex, which is an essential component of the rod photo-
transduction cascade and which is the same gene responsible for the Pde6brd1 phenotype. Under 
normal circumstances, photon capture by rhodopsin triggers a conformational change in its 
protein structure allowing it to bind and stimulate the G-protein, transducin. Afterwards, transducin 
binds the γ-subunit PDE6 downstream signaling cascade in which PDE is responsible for the 
conversion of cGMP to 5’-GMP. The rapid hydrolysis of cGMP leads to the closure of cGMP-
gated cation channels and hyperpolarization of the rod cell. In the case of the Pde6brd10 mouse, 
loss of β subunit activity leads to insufficient closure of these channels and constitutive influx of 
cations leading to activation of cell death signaling cascades (Wang et al., 2017). Light driven 
responses measured with electroretinogram (ERG) are severely reduced in these animals and 
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essentially absent by two months of age. Rod degeneration typically begins around PN16-18 with 
peak death occurring near PN25 (Gargini et al., 2007).  
I assessed the neuroprotective potential of these approaches on visual function, 
structural morphology, and preservation of photoreceptors. Potential mechanisms of this 
neuroprotective effect by examining the expression of markers indicative of mTOR activation. In 
addition, I investigated the long-term safety of these approaches with respect to the potential for 
oncogenic proliferation of retinal neurons and effects upon other retinal cell types.  
 
Results 
Design and characterization of mTOR activation vectors 
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AAV7m8 is a variant of AAV2 generated through in vivo selection and displays enhanced 
retinal and cellular transduction properties (Dalkara 2013, Khabou 2016). We generated AAV7m8 
vectors encoding an enhanced green fluorescent protein reporter (AAV.eGFP), a hyperactive 
versions of human AKT3 (AAV.AKT3), and a constitutively active Rheb mutant (AAV.caRheb) 
(Figure 3.9A). The AKT3 transgene contains an N-terminal myristoylation (MYR) sequence, 
thereby enhancing membrane targeting and localization (McIlhinney, 1998). The Rheb transgene 
contains the canonical S16H mutation which confers resistance to TSC-mediated GAP activity 
(Yan et al., 2006). Transduction of 84-31 cells with the AAV.caRheb or AAV.AKT3 vectors 
displays robust expression of target gene mRNA compared to untreated controls (Figures 3.9B-
C). Subretinal delivery of AAV7m8 displays robust labeling of retinal neurons occupying the outer 
nuclear layer, including photoreceptors and retinal pigment epithelia (RPE) in wild-type animals 
(Figures 3.9D-E). Likewise, this vector exerts similar effects when administered to the Pde6brd10 
retina (Figures 3.9G-H). Co-injection with a reporter vector localize specifically to the area of 
subretinal delivery (Figures 3.9F-H) allowing adequate tracing of the treated retinal region.     
caRheb gene transfer fails to attenuate retinal degeneration in the Pde6brd10 mouse 
I investigated the effect of caRheb gene augmentation in the Pde6brd10 retina. Animals 
received subretinal injection of AAV vectors at PN13-14. Visual function was measured with 
electroretinogram (ERG) and optokinetic response (OKR). Retinal histology was examined at 
PN45 to determine the effects of AAV.caRheb on photoreceptor survival (Figure 3.10A-C). 
Quantification of total ONL thickness per retina displayed insignificant preservation of 
photoreceptors following treatment with AAV.caRheb compared to untreated controls or animals 
treated with the AAV.eGFP reporter alone (Figure 3.10B). In addition to total ONL thickness, I 
measured the number of GFP+ ONL cells per 200 µm sections of transduced regions in rd10 
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retina treated with AAV.eGFP alone or in combination with AAV.caRheb. Once again, I did not 
observe statistically different changes in ONL cell numbers between these treatments (Figure 
3.10C). Furthermore, AAV.caRheb did not preserve visual function compared to control 
treatments as measured with ERG (Figures 3.10D-F) and OKR (Figure 3.10G). Collectively, 
these data suggest caRheb gene transfer does not promote photoreceptor neuroprotection in the 
Pde6brd10 mouse retina.  
 
 
 
 
 
 
 
 
 
 
 
Interestingly, the AAV.caRheb vector displays differential effects with respect to mTORC1 
activation within a cell-based setting and in vivo (Figure 3.11). Transduction of 84-31 cells with 
the AAV.caRheb vector promotes robust activation of mTORC1 as measured with western blot 
analysis. Specifically, protein samples derived from cells treated with AAV.caRheb demonstrate 
enhanced presence of the canonical mTORC1 marker, phosphorylated ribosomal protein S6 
 
59 
(pS6Ser240/244) whereas AAV.eGFP and untreated cells do not show such levels. However, 
following subretinal delivery the AAV.caRheb vector did not display activation of mTORC1 within 
photoreceptors or other retinal cell types as assayed by immunohistochemical staining for 
pS6Ser240/244 activation marker. These results suggest retinal or photoreceptor-intrinsic 
mechanisms may inhibit or deter caRheb from activating mTORC1. 
 
 
 
 
 
 
 
 
 
 
 
 
AKT3 gene augmentation promotes photoreceptor survival and structural preservation in the 
Pde6brd10 retina 
I examined the effect of AKT3 gene augmentation on photoreceptor survival and 
structural integrity in the Pde6brd10 retina. Histological analysis of retinal architecture at PN30 and 
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PN45 revealed a potent neuroprotective effect upon outer nuclear layer cells localized specifically 
to regions of vector transduction co-labeled with reporter vector fluorescence (Figures 3.12A-J). I 
observed similar measurements for total ONL thickness in untreated and AAV.GFP injected eyes 
at PN30. Co-injection of AAV.GFP with AAV.AKT3 provided statistically significant preservation of 
total ONL thickness compared to control eyes (Figure 3.12L). Furthermore, this neuroprotective 
effect was sustained in retinal samples harvested at later points in the degenerative process 
(PN45) (Figures 3.12K-L). In addition to attenuation of cellular numbers, immunostaining with a 
canonical marker of the cone cell body (CAR) displayed morphological preservation compared to 
non-transduced retinal regions and control eyes (Figures 3.12F-J). Remarkably, immunostaining 
for rhodopsin revealed enhanced preservation of rod outer segments at the PN30 harvest point 
compared to age-matched controls suggesting the importance of this pathway in mediating 
survival and maintenance of both photoreceptor subtypes (Figures 3.12A-E).  
Effect of AKT3 gene transfer on retinal and visual function in the Pde6brd10 retina. 
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I assessed retinal and visual function at the PN30 and PN45 time points with 
electroretinography (ERG) and optokinetic response (OKR) measurements, respectively. 
Combined rod-cone responses from eyes treated subretinally with AAV.AKT3 displayed improved 
a-wave (Figure 3.13A) amplitudes compared to both untreated and AAV.eGFP treated controls 
at PN30. In addition, eyes treated with AAV.AKT3 also elicited increased mixed b-wave 
responses (Figure 3.13B) compared to the AAV.eGFP treated eyes but not untreated eyes at this 
time point.  However, there were no significant differences between treatment groups at PN45 
(Figures 3.13B). We also measured the cone-specific b-wave response but did not observe 
statistically significant differences between treatment groups at neither time point (Figure 3.13C). 
We examined visual acuity in response to gene transfer by measuring the optokinetic response 
(OKR). Data represent the right/left eye ratio of these recordings in which untreated left eyes 
served as within-animal controls while right eyes were treated with AAV.eGFP alone or in 
combination with AAV.AKT3. Treatment with AAV.AKT3 did not maintain visual acuity compared 
to the AAV.eGFP control at PN30 or PN45 (Figure 3.13D). Collectively, this data suggests AKT3 
gene augmentation provides some degree of visual preservation during early-mid stage disease 
but does not retain visual function in later stage degeneration.  
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AKT3 gene transfer stimulates biosynthetic and cell survival pathways 
 
Prior investigations underscore the contribution of mTOR in mediating photoreceptor 
neuroprotection in RP models (Tsang et al., 2014; Venkatesh et al., 2015; Zhang et al., 2016). 
Likewise, I hypothesized that the AKT3-induced neuroprotective response was affiliated with 
activation of pathways associated with anabolism and cell survival by immunostaining retinal 
sections with antibodies directed against canonical downstream markers indicative of mTOR 
activation (Figure 3.14). Regions of the retina transduced specifically with AAV.AKT3 
demonstrate enhanced expression of phosphorylated ribosomal protein S6 (pS6) compared to 
non-transduced areas and control treatments (Figures 3.14E-H). This finding builds upon 
previous evidence suggesting the importance of mTORC1 in maintaining photoreceptor 
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homeostasis in the degenerative retina (Venkatesh et al., 2015; Zhang et al., 2016). Interestingly, 
I also observed increased expression of an mTORC2 marker (pAKT-S473) within regions 
specifically exposed to AKT3 gene augmentation, suggesting stimulation of additional functions 
associated with cell survival and stress resistance (Figures 3.14A-D). Retinal sections obtained 
from untreated and AAV.GFP control groups did not display enhanced expression of these 
markers implying the AKT3-induced neuroprotection is, at least, partially driven by such 
mechanisms (Figures 3.14D, H).    
AKT3 does not breach photoreceptor quiescence but activates müller glia 
Dysregulated AKT signaling is a common hallmark of many human cancers (Altomare et 
al., 2005). I examined the effect of AKT3 augmentation on retinal quiescence by immunostaining 
with canonical markers of cellular proliferation. Expression of Ki67 was restricted to cells 
occupying the ganglion cell layer in untreated Pde6brd10 retinas and those treated with 
AAV.eGFP. Co-staining with antibodies directed against GFAP identified these Ki67+ cells as 
müller glia, which provide support to other retinal cell types through mediating neurotrophic factor 
release, regulation of extracellular ion balance, and debris scavenging (Goldman, 2014; 
Reichenbach et al., 2013). Importantly, cells occupying the ONL did not display positive 
immunoreactivity for the Ki67 marker suggesting the AKT3-induced protective response was not 
a byproduct of quiescent escape (Figures 3.15H-I). Interestingly, müller cells within regions of the 
retina specifically transduced with AAV.AKT3 demonstrate morphological changes representative 
of astrogliosis such as upregulation of GFAP expression and spreading of their processes 
throughout different cellular layers (Figures 3.15G-I). Immunostaining against PCNA, an 
additional marker of cell proliferation, did not display reactivity in any of the aforementioned 
treatment groups (data not shown) providing additional support that AKT3-induced 
neuroprotective effects are preservative rather than proliferative with respect to photoreceptors.  
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Long-term constitutive AKT3 overexpression leads to retinal disorganization in wild-type animals. 
I examined the effects of long-term AAV.AKT3 overexpression in the C57BL/6 (wild-type) 
retina. Animals received subretinal injections of AAV.AKT3/AAV.eGFP in one eye and AAV.eGFP 
in the contralateral eye. Eyes were harvested for histological analysis at PN125. Retinal regions 
exposed to AAV.AKT3 transduction demonstrate profound disorganization of retinal layers and 
loss of photoreceptor structure (Figure 3.16). Moreover, these regions once again display an 
increase in histological markers of reactive gliosis previously observed in Pde6brd10 retinal 
samples (Figure 3.16G-I). Non-transduced regions within the wild-type samples appear 
phenotypically normal (Figure 3.16A-C). Moreover, eyes that were administered AAV.eGFP 
alone also show no histological findings suggestive of retinal disorganization or cellular loss 
(Figure 3.16D-F, J). These results suggest long-term stimulation of anabolic metabolism via 
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AKT3 overexpression and/or widespread expression through incorporation of a constitutive 
promoter lead to aberrant changes in retinal structure and homeostasis.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Photoreceptor-restricted AKT3 gene augmentation promotes neuroprotection in the Pde6brd10 
retina but does not stimulate reactive gliosis 
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I hypothesized that photoreceptor-specific augmentation of AKT3 could mediate similar 
neuroprotective effects as the ubiquitously expressed vector without adverse effects on other 
retinal cell types. I generated an additional AAV7m8 vector that drives AKT3 transgene 
expression regulated by the photoreceptor-specific rhodopsin kinase 1 (GRK1) promoter (Figure 
3.17A). Subretinal delivery to Pde6brd10 animals mediates neuroprotective effects upon 
photoreceptor structure and function. Immunolabeling retinal sections with antibodies directed 
against AKT demonstrate specific expression within the photoreceptor layer (Figure 3.17E). 
Moreover, photoreceptor-specific AKT3 expression led to increased ONL thickness compared to 
untreated or AAV.eGFP administration alone (Figure 3.17F). Similar to previous findings with the 
ubiquitous AKT3 vector, photoreceptor-specific AKT3 overexpression mediated preservation of 
mixed a- and b-wave responses at the PN30 time point. Moreover, this vector was able to 
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preserve mixed b-wave responses at the PN45 timepoint compared to eyes that received the 
AAV.eGFP control vector (Figure 
3.17C). Similar to the ubiquitous 
vector, cone-specific responses 
remained similar between treatment 
groups (Figure 3.17D). I hypothesized 
that reactive gliosis stimulated by 
AKT3 overexpression was attributed to 
off target gene expression within 
muller glia and photoreceptor-selective 
transgene expression of AKT3 would 
not stimulate glial activation and deter 
this cellular phenotype. Pde6brd10 
retinas treated with AAV.GRK1.AKT3 
were stained with antibodies directed 
against GFAP (muller cell marker) and 
Ki67 (proliferative marker). Untreated 
and AAV.GRK1.AKT3 regions of the 
retina display similar qualitative 
findings with respect to muller glial activity, supporting the role of ubiquitous AKT3 gene transfer 
in stimulating reactive gliosis. Thus, incorporation of the photoreceptor-specific promoter confers 
both safety and efficacy, at least through the 45 day time point (Figure 3.18).  
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Methods 
Animals 
C57Bl/6 and Pde6brd10 mice were obtained from the Jackson Laboratory and raised in a 
12-hour light/dark cycle. Animals were housed at the University of Pennsylvania vivarium in 
compliance with ARVO guidelines on the care and use of laboratory animals as well as with 
institutional and federal regulations. 
AAV vectors 
A plasmid encoding the human AKT3 cDNA sequence containing N-terminal 
myristoylation (MYR) and HA tags was kindly provided by William Sellers (addgene plasmid 
#9017). The MYR-HA-hAKT3 sequence was amplified and cloned into an AAV proviral 
expression plasmid using the In-Fusion HD cloning system (Clonetech). The human Rheb cDNA 
clone was obtained from Origene. Inverse PCR mutagenesis was employed to create the S16H 
mutation with the following primer sequences: 5’ [phospho] CACGTGGGGAAATCCTCATTGAC 
3’ (S16H Forward) and 5’ CCGGTAGCCCAGGAT 3’.  For production of viral vectors, the helper 
plasmid expressing AAV7m8 Cap was kindly provided by John Flannery and David Schaffer 
(addgene plasmid #64839). AAV7m8-AKT3 and AAV7m8-eGFP vectors were generated using 
previously described methods (Ramachandran et al., 2017) and purified with CsCl gradient by the 
Center for Advanced Retinal and Ocular Therapeutics (CAROT) research vector core (University 
of Pennsylvania, PA, USA). 
Cell culture 
84-31 cells were kindly provided by Dr. James Wilson (University of Pennsylvania) and 
were cultured in DMEM-GlutaMax supplemented with 10% FBS and 1% penicillin-streptomycin. 
For AAV transductions, 84-31 cells were plated at a density of 2.5x105 cells/well in a 6-well dish. 
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Afterwards, cells were immediately transduced with AAV7m8 vectors at 1x106 multiplicity of 
infection (MOI). Cells were maintained at 37oC with 5% CO2. 
RNA isolation and RT-qPCR 
RNA was isolated from 84-31 cells using the Macherey-Nagel Nucleospin RNA kit. First-
strand cDNA synthesis was performed using 500 ng of total RNA with the SuperScript III first-
strand synthesis system according to manufacturer’s protocol. Real-time PCR was performed 
with the Applied Biosystems 7500 Fast system using the Power SYBR green PCR master mix 
(Invitrogen). The following primer sequences were used: 5’ CCACTCCTCCACCTTTGAC 3’ 
(human GAPDH Forward), 5’ ACCCTGTTGCTGTAGCCA 3’ (human GAPDH Reverse), 5’ 
ACTCCTACGATCCAACCATAGA 3’ (human Rheb Forward), 5’ 
TGGAGTATGTCTGAGGAAAGATAGA 3’ (human Rheb Reverse), 5’ 
AGGATGGTATGGACTGCATGG 3’ (human AKT3 Forward), and 5’ 
GTCCACTTGCAGAGTAGGAAAA 3’ (human AKT3 Reverse). Relative gene expression was 
quantified with the ΔΔCT method and normalized to GAPDH. 
Subretinal Injections 
Subretinal injections were performed as previously described (Dooley et al., 2018). Each 
retina received 1 uL of vector preparation. Eyes injected with AAV.eGFP received 2x109 total 
vector genomes. Eyes that were co-injected with AAV.eGFP plus AAV.AKT3 or AAV.caRheb 
were dosed with 1x109 vector genomes per vector to achieve 2x109 total vector genomes. 
Electroretinogram 
Mice were anesthetized and maintained as previously described. Pupils were dilated with 
1% tropicamide (Alcon Laboratories, Fort Worth, TX). Clear plastic contact lenses with embedded 
platinum wires were used to record light responses, and a platinum wire loop was placed into the 
animal’s mouth to serve as a reference electrode. ERGs were recorded with the Espion E2 
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system (Diagnosys, Lowell, MA). Three ERG responses were recorded with the following 
parameters: scotopic response (dark adaption, 0.01 scot cd s m-2 stimulus), maximum rod-cone 
response (dark adaptation, 500 scot cd s m-2 stimulus), maximum cone response (30 scot cd m−2 
adapting steady background light, 500 scot cd s m−2 stimulus). 
Optokinetic Response 
Visual acuity was assessed by measuring the optokinetic response (OKR) using the 
OptoMotry software and apparatus (Cerebral Mechanics, Inc, Medicine Hat, AB, Canada) as 
previously described (Prusky et al., 2004). Recordings were performed by an investigator blinded 
to the ocular treatments. 
Immunohistochemistry 
Eyes were enucleated, harvested, and prepared as frozen sections as previously 
described (Dooley et al., 2018). Sections were incubated in blocking buffer containing PBS, 10% 
normal goat serum (CST), and 2% Triton X-100 for one hour at room temperature. Afterwards, 
sections were incubated in primary antibody solution overnight in a humidified chamber 
containing the previously described components and combinations of the following antibodies: 
rabbit anti-cone arrestin (1:400; Millipore #ab15282), rabbit anti-phospho-S6-Ser240/244 (1:100; 
CST #5364), rabbit anti-phospho-AKT-Ser273 (1:100; CST #4060), mouse anti-rhodopsin (1:400; 
Abcam #ab5417), rabbit anti-HA (1:100; CST #3724), rabbit anti-Ki67 (1:400; Abcam #ab15580), 
mouse anti-PCNA (1:400; Abcam #ab29), chicken anti-GFAP (1:400; Abcam #ab4674), rabbit 
anti-AKT (1:100; CST #4691). Following primary antibody incubation, sections were washed three 
times with PBS and incubated in secondary antibody solution for 2 hours at room temperature in 
a humidified chamber containing PBS, 10% normal goat serum, 2% Triton X-100, and 
combination of the following secondary antibodies: alexa fluor-594 goat anti-chicken (1:500; 
Abcam #ab150176), alexa fluor-594 goat anti-mouse (1:500; #ab150116), alexa fluor-594 goat 
anti-rabbit (1:500; Abcam #ab150080), Cy5-conjugated goat anti-rabbit (1:500; KPL #072-02-15-
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16). Sections were removed from secondary antibody incubation and washed three times with 
PBS.  Sections stained for the presence of phosphorylated antigens were incubated and washed 
in solutions containing TBS instead of PBS.  
ONL measurements 
Whole retinal sections were tiled using a 40X objective with the EVOS FL Auto 2 cell 
imaging system. In each image, ONL thickness was measured at three equidistant points spaced 
75-100 µm apart. These measurements were averaged between all images to represent the 
average ONL thickness of the section. Three retinal sections were averaged per sample. ONL 
numbers from specific regions of the retina transduced with vector were quantified by counting 
the number of GFP+ ONL cells per a 200 µm area. Once again, three retinal sections were 
averaged per sample to acquire these measurements.  
Western blotting 
Protein samples were separated with the NuPage electrophoresis system (Thermo 
Fisher). Samples were heated at 70oC and loaded onto 4-12% Bis-Tris protein gels (Thermo 
Fisher). Separated proteins were then transferred to a PVDF membrane with the XCell II blot 
module (Thermo Fisher) at 35 volts for 1.5 hours. Following protein transfer, membranes were 
incubated in tris-buffered saline containing 0.1% (v/v) Tween 20 (BioRad) (TBST) and 5% (w/v) 
bovine serum albumin (BSA; Sigma-Aldrich) for 1 hour at room temperature. Afterwards, blots 
were incubated in the previously described solution containing the following primary antibodies: 
rabbit anti-phospho-S6-Ser240/244 (1:1000; CST #5364), rabbit anti-S6 (1:1000; CST #2217), 
rabbit anti-GAPDH (1:1000; CST #5174). Primary antibody incubation occurred overnight at 4oC. 
Blots were removed from primary antibody solution and washed three times in TBST for 5 
minutes each. Afterwards, they were placed in secondary antibody solution composed of TBST, 
5% BSA, and HRP-conjugated anti-rabbit ECL (1:10,000; GE Healthcare) for 1 hour at room 
temperature. Membranes were washed three times in TBST followed by incubation with ECL2 
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(Thermo Fisher) according to manufacturer’s instructions for 5 minutes. Finally, membranes were 
imaged using the Amersham Imager 600 (GE Healthcare) with chemiluminescence settings.  
Statistics 
All data are represented as means ± SEM unless otherwise indicated. Differences 
between two treatment groups were compared using an unpaired student’s t-test. Differences 
between three or more experimental groups were compared using a one-way ANOVA followed by 
Turkey’s honest significant difference test. Calculations for statistical significance were 
determined using GraphPad Prism 7.0. Differences were considered statistically significant at P < 
0.05 
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CHAPTER 4 CRISPR/Cas9 activation enhances in vitro potency of AAV vectors 
regulated by tissue-specific promoters 
 
Cell-based potency assays for drug development and approval 
Potency of a drug product is defined as the biological activity directly related to a clinical 
endpoint. The US Food and Drug Administration (FDA) requires a validated potency assay prior 
to the release of a new drug to ensure its identity, purity, and stability (. Furthermore, potency 
assays should encompass features that enable a quantitative measurement of biological activity 
that is specific to the intended function of the product. Assay parameters can be designed to 
interrogate functional features of the product within animal models or cell-based systems. 
However, cell-based potency assays are highly preferred due to the greater time, resources, 
variability, and ethical considerations often associated with animal use (FDA).     
Viral vectors 
occupy a unique space 
in drug development as 
these are highly 
sophisticated biological 
particles composed of 
protein and nucleic 
acid components. Their 
structural and 
functional complexity 
presents a variety of challenges in the design and implementation of potency assays for specific 
disease targets. Figure 4.1 depicts the cell-based potency assay developed for Luxturna, which 
is an AAV2-based therapy for vision loss associated with RPE65 mutations. The vector 
expression cassette encodes a codon-optimized version of the human RPE65 cDNA driven by 
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the ubiquitous CAG promoter (Figure 4.1A). Cell lysates are derived from transduction of 
HEK293 cells that constitutively express LRAT (lecithin retinol acyltransferase). Afterwards, 
lysates are incubated in the presence of all-trans-retinol and CRALBP to reconstitute a portion of 
the visual cycle and generate of the desired outcome measure, 11-cis-retinol. Constitutively 
expressed LRAT converts the all-trans-retinol substrate to all-trans-retinyl-ester. Afterwards, the 
RPE65 protein provided in trans by the AAV expression cassette stimulate the conversion of all-
trans-retinyl-ester to 11-cis-retinol, which is detected by liquid chromatography with tandem mass 
spectrometry (LC-MS/MS) (Figure 4.1B). Features associated with the AAV serotype and 
expression cassette are favorable. Foremost, HEK293 cells are readily infected by the AAV2 
capsid. In addition, transgene expression is driven by a highly active ubiquitous promoter, thereby 
providing substantial levels of RPE65 protein to carry out the desired enzymatic activities of the 
functional assay.  
 In addition to capsid limitations, another a major challenge concerns the selection of 
tissue or cell-specific regulatory elements to control transgene expression. In many cases, these 
promoters provide specificity and robust levels of expression in vivo but display relatively poor 
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activity when applied to in vitro systems. In the context of retinal gene transfer, several promoter 
sequences enable selective and stable gene expression patterns in specific neuronal populations 
such as photoreceptors (Chaffiol et al., 2017; Flannery et al., 1997; Hanlon et al., 2017; Khani et 
al., 2017). AAV vectors driven by such regulatory elements are expected to demonstrate robust 
safety and efficacy profiles in pre-clinical models of inherited retinal degeneration, underscoring 
their translational potential and continued development for clinical application (Boye et al., 2013; 
Boye et al., 2015; Petersen-Jones et al., 2018). However, these elements display exceptionally 
poor and often times undetectable activity when applied to in vitro systems (Figure 4.2C-D) 
thereby impeding their use in cell-based potency assays. 
CRISPR/Cas9 and genome editing 
Recent developments surrounding gene editing technologies such as CRISPR/Cas9 
provide a powerful means to create simple, rapid, and precise modifications to genomic DNA 
sequences (Cong et al., 2013; Jinek et al., 2013). The canonical system is composed of two 
components. Cas9 is an RNA-guided DNA 
endonuclease derived from various bacterial 
species with Streptococcus pyogenes Cas9 
(SpCas9) being the most well characterized and 
extensively utilized variant to date (Figure 4.3). The 
guide RNA (sgRNA) is a small RNA molecule 
composed of a conserved scaffold sequence 
important for binding to Cas9 and another 
approximately 20 basepair sequence that contains 
homology to the genomic target sequence of 
interest. The target sequence must contain a trinucleotide sequence, 5’-NGG-3’, termed the 
protospacer adjacent motif (PAM). The presence of the PAM sequence allows Cas9 to destabilize 
the double-stranded DNA helix and promote binding of the sgRNA to its homologous genomic 
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sequence. If these sequences form a successful RNA:DNA duplex, the nuclease domain of the 
Cas9 will mediate a double-stranded cut in the target sequence a few basepairs upstream of the 
PAM recognition site. The presence of a double-stranded break (DSB) elicits components of the 
DNA damage response. Breaks are typically resolved through the nonhomologous end joining 
(NHEJ) repair pathway. This process does not retain sequence fidelity and leads to the random 
insertions or deletions of nucleotides (indels) at the break site, thereby potentially generating a 
termination codon within the open reading frame and disrupting gene function (Brinkman et al., 
2018). This mechanism is used extensively to 
generate gene-specific knockouts within human cells 
for numerous biological applications including disease 
modeling, pathway interrogation, and screening of 
drug targets (Dow, 2015; Kurata et al., 2017; Shalem 
et al., 2014). Beyond NHEJ, site-directed knock-in of a 
donor template can be achieved utilizing the homology 
directed repair (HDR) pathway. This requires inclusion 
of a donor template sequence flanked by sites that are 
homologous to the DSB region (Brinkman et al., 2018). 
Gene transfer strategies utilizing HDR-associated gene knock-in were shown to improve 
phenotypic outcomes in a mouse model of ornithine transcarbamylase (OTC) deficiency (Yang et 
al., 2016).   
Genome engineering with targeted transcriptional effectors 
In addition to gene editing, more recently described systems have employed catalytically 
inactive variants of Cas9 (dCas9) tethered to effector domains for enabling selective regulation of 
transcriptional activity (Figure 4.4). Inactivation of Cas9 catalytic activity is achieved by mutating 
two amino acids critical to endonuclease function (Qi et al., 2013). While these mutations 
successfully ablate nuclease activity, Cas9 still retains all functions with respect to DNA binding 
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and recognition. Based on this core platform, numerous approaches have been described to 
achieve various modalities of gene regulation including activation, repression, or epigenetic 
remodeling (Kabadi et al., 2014; Perez-Pinera et al., 2013; Qi et al., 2013). Qi et al. (2013) were 
the first to report the utility of dCas9-mediated transcriptional regulation and elucidated the ability 
of dCas9 to repress gene expression by blocking RNA polymerase (RNAP) binding during 
transcriptional elongation. Perez-Pinera et al. (2013) developed an approach to stimulate gene 
expression from target genes by fusing dCas9 to the canonical VP64 transactivation domain 
derived from Herpes simplex virus. Such systems have improved our fundamental understanding 
of gene function through incredibly 
rapid, specific, and high-throughput 
genetic screening methods that 
utilize dCas9-mediated gene 
repression (Bak et al., 2017; Zheng 
et al., 2018). Furthermore, CRISPR-
based gene activation has 
demonstrated therapeutic utility in 
pre-clinical models of type 1 
diabetes, kidney disease, and muscular dystrophy (Liao et al., 2017).  Building upon these 
canonical systems, Chavez et al. (2015) engineered a synthetic transactivation complex, termed 
VPR, which combines activities of the VP64, p65, and Rta activation domains (Figure 4.5A). VPR 
was shown to stimulate higher levels of gene expression compared to dCas9 fused to the 
canonical VP64 transactivation domain (Figure 4.5B-C). I hypothesized that such an approach 
could provide an effective means to activate tissue-specific promoters from AAV expression 
cassettes in cell-based functional and potency assays.  
 
Results 
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Rhodopsine kinase 1 (GRK1) and cone arrestin (CAR) promoters display robust activity in 
photoreceptors but poor activity in cell-based systems 
I generated AAV8 reporter vectors driven by the cytomegalovirus enhancer/chicken beta 
actin (CAG) hybrid promoter, human rhodopsin kinase (GRK1) promoter, or human cone arrestin 
(CAR) promoter (Figure 4.2A). Subretinal administration of vectors demonstrates robust activity 
in vivo with fundoscopic analysis and immunohistochemistry of retinal sections (Figure 4.2B). 
Vectors regulated by the ubiquitous CAG promoter display expression in multiple retinal cell types 
in the outer and inner nuclear layers. AAV8.GRK1.eGFP activity was restricted specifically to 
photoreceptors, while AAV8.CAR.eGFP vectors display leaky expression within photoreceptors 
and RPE. AAV transduction with these photoreceptor promoters in vitro reveals exceptionally 
poor activity when compared to CAG driven vectors as demonstrated by microscopy and 
fluorescence intensity (Figure 4.2C-D). These results underscore the major discrepancy in vector 
activity in vivo versus cell-based systems when transgene expression is regulated by a tissue-
specific promoter. Moreover, the results highlight the major limitation of building a cell-based 
potency assay for gene transfer vectors regulated by tissue or cell-specific promoters.    
In vitro activation of photoreceptor promoters with dCas9 transcriptional activation 
I hypothesized that recently characterized dCas9-based transcriptional activators would 
allow stimulation of photoreceptor promoters in the context of an in vitro system. I screened 
twenty unique guide RNAs targeting the GRK1 or CAR promoter sequences using a 
fluorescence-based reporter assay. Guide RNAs were cloned into expression plasmids encoding 
enhanced green fluorescent protein (eGFP) driven by either the GRK1 or CAR promoters (Figure 
4.6A). These constructs were transfected into 84-31 cells that stably express dCas9 fused to the 
VPR transactivation complex (84-31.VPR). Fluorescence readings 48 hours post-transfection 
revealed differential effects upon reporter expression driven by photoreceptor promoters (Figure 
4.6B-C). Most guide sequences provided a modest increase in reporter expression compared to 
cells transfected with plasmids harboring an empty sgRNA cassette (NG). Guide RNA candidate 
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#9 demonstrated the most potent stimulation of GRK1 driven reporter expression, while sgRNA 
candidates #4 and #10 stimulated similar and robust levels of reporter activity (Figure 4.6B-C). 
Likewise, fluorescent microscopy revealed robust induction of eGFP protein expression in 84-
31.VPR cells transfected with these top performing sgRNA/reporter plasmids compared to empty 
guide control plasmids (Figure 4.6D). 
dCas9-mediated transcriptional activation stimulates tissue-specific promoter expression from 
AAV vectors 
I generated a panel of stable cell lines that co-express dCas9.VPR and a top performing 
sgRNA candidate targeting the GKR1 promoter (84-31.GRK1.9) or CAR promoter (84-31.CAR.4) 
from a single lentiviral expression cassette (Figure 4.7A). Transduction with two different AAV 
serotypes demonstrated robust activation of transgene expression specifically within 84-31 cell 
lines co-expressing the sgRNA and dCas9.VPR (Figure 4.7B-C). Moreover, photoreceptor 
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promoter expression was shown to increase in a dose-dependent manner (Figure 4.7C). To 
determine whether this approach could be broadly applied to other cell lines, I examined vector 
expression in ARPE-19 cells, which display morphological and biochemical features of retinal 
pigment epithelia (RPE). Transduction of ARPE-19 cells selected to stably co-express 
dCas9.VPR and sgRNA9 (ARPE-19.GRK1.9) resulted in enhanced levels of reporter expression 
compared to control cells (Figure 4.7D). Collectively, these results demonstrate the potent and 
broad applicability of this system for activating tissue specific promoters from AAV expression 
cassettes irrespective of cell line. 
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Multiplexed CRISPR-dCas9 promoter targeting amplifies AAV transgene expression 
 
 
 
 
 
 
 
 
 
 
 
 
Prior reports suggest co-expression of multiple guide RNA sequences (multiplexing) 
targeting a single promoter region may vastly improve dCas9-mediated gene activation. Likewise, 
I hypothesized that inclusion of a second guide RNA could enhance the activation of 
photoreceptor promoters from AAV genomes. We engineered a lentiviral vector encoding dCas9-
VPR and the two top performing guide RNA sequences targeting the CAR promoter (Figure 
4.8A). Similar to previous experiments, I generated a stable cell line (84-31-CAR.4.10) and 
selected positively transduced clones with puromycin incubation. These cells display greater 
levels of reporter gene expression as assayed by microscopy, fluorescence intensity readings, 
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and gene expression analysis (Figure 4.8B-D). Similar to previous experiments, the degree of 
reporter gene expression increased in a dose-dependent manner suggesting the importance of 
AAV genome copies as the rate limiting determinant of promoter activation.   
AAVR co-expression mediates a synergistic effect upon AAV promoter activation 
 
 
 
 
 
 
 
 
Recent studies identified and characterized a “universal” transmembrane receptor for 
AAV infection denoted as AAVR (Pillay et al., 2016; Pillay et al., 2017; Dudek et al., 2018) 
(Figure 4.9).  I generated 84-31 cells that stably express AAVR with a lentiviral vector (Figure 
4.10A). Transduction of 84-31 cells that stably overexpress AAVR display differential effects upon 
reporter gene expression compared to control cells (Figure 4.10B-C). Surprisingly, transduction 
with many serotypes was inhibited compared to 84-31 control cells suggesting a discrepancy 
between AAVR activity and capsid or cell line dependent properties. Importantly, the transduction 
efficiency of some clinically relevant capsids, including AAV8 and AAV8BP2, was enhanced with 
AAVR supplementation. Based on these findings, I hypothesized that enhanced vector uptake 
through the AAVR pathway would provide additional substrate for the dCas9 activating 
components and subsequently improve vector transgene expression. 84-31 and 84-31-CAR.4.10 
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cells were similarly transduced with a lentiviral vector driving AAVR overexpression, and positive 
clones were selected with blasticidin. Transduction of 84-31-CAR4.10.AAVR cells with 
AAV8.CAR.eGFP demonstrates superior transgene expression compared to control cell lines as 
detected by microscopy and RT-qPCR (Figure 4.10D-E). Collectively, these results highlight the 
synergistic value of enhancing AAV. Furthermore, they once again suggest vector genome copies 
as the limiting factor in achieving substantial tissue-specific promoter activation from AAV 
transgene cassettes. 
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Methods 
Plasmid generation 
The pAAV-U6-sgRNA-CMV-eGFP-KASH plasmid was kindly supplied by Hetian Lei 
(Addgene #85451). The eGFP-KASH coding sequence was removed by digestion with AgeI-HF 
and EcoRI-HIF (NEB), and the wild-type eGFP sequence was amplified and restored between 
these sites. In addition, the CMV promoter cassette was removed by digestion with NheI-HF and 
SpeI-HF (NEB) and replaced with the GRK1 or CAR promoter sequences. Guide RNA sequences 
targeting either promoter were cloned between the SapI sites between the U6 promoter and 
guide scaffold. The pLenti-EF1α-dCas9-VPR-2A-Puro plasmid was a kind gift from Kristen 
Brennand (Addgene #99373). pLentiCRISPRv2 was kindly provided by Feng Zhang (Addgene 
#52961). Top performing candidate guide RNAs were cloned between the BsmBI (NEB) sites of 
pLentiCRISPRv2. Afterwards, the SpCas9-2A sequence was removed by digestion with XbaI-HF 
and BamHI-HF (NEB). The dCas9-VPR-2A sequence was amplified and cloned into the 
XbaI/BamHI digested pLentiCRISPRv2 with the In-Fusion HD cloning system (Clonetech) to 
create lentiviral expression plasmids that co-express a single guide RNA and dCas9-VPR-2A-
Puro. A plasmid encoding AAVR-FLAG was a kind gift from Jan Carette (Stanford University). 
The AAVR-FLAG sequence was amplified and cloned into a lentiviral expression vector 
containing a downstream blasticidin resistance cassette. All plasmids were propagated in One 
Shot Stbl3 competent cells (Invitrogen). 
Cell culture 
HEK293T and ARPE-19 cells were supplied by ATCC (Manassas, VA, USA). HEK293T 
cells were cultured in DMEM-GlutaMax (Gibco) supplemented with 10% FBS and 1% penicillin-
streptomycin. ARPE-19 cells were maintained in Dulbecco’s modified eagle medium: nutrient 
mixture F-12 (DMEM/F12; Gibco) and supplemented with 10% fetal bovine serum (FBS) and 1% 
penicillin-streptomycin. 84-31 cells were provided by James M. Wilson (University of 
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Pennsylvania) and were cultured in DMEM-GlutaMax supplemented with 10% FBS and 1% 
penicillin-streptomycin. All cell lines were grown at 37oC with 5% CO2. Cell lines stably 
transduced with lentiviral vectors were selected and maintained in medium containing 1 µg/mL 
puromycin or 10 µg/mL blasticidin-S.  
Guide RNA selection 
Candidate guide RNA sequences were identified with web-based design tools including 
CRISPR Design (crispr.mit.edu) and CRISPR-ERA (crispr-era.stanford.edu). 
Lentiviral vector production 
2x106 HEK293T cells were plated in 10cm dishes. The following day cells were 
transfected with 6 ug of the appropriate lentiviral expression plasmid, 4 ug psPAX2 (supplied by 
Didier Trono; Addgene #12260), and 2 ug pMDG.2 (supplied by Didier Trono; Addgene #12259) 
combined with 16 uL of Lipofectamine 2000 (Invitrogen) according to manufacturer’s protocol. 
Cells were refed with fresh media the following day. Media containing lentiviral particles was 
harvested 48 and 72 hours post-transfection, pooled, and stored at -80C until use.  
AAV vector production 
AAV vectors were generated using previously described methods (McDougald et al., 
2018) and purified with CsCl gradient by the CAROT research vector core at the University of 
Pennsylvania. 
In vitro AAV transduction and fluorescence intensity measurements 
5x104 cells were plated into individual wells of 96-well black bottom dishes. Afterwards, 
cells were immediately transduced with AAV vectors at the MOIs indicated. eGFP fluorescence 
was quantified at 48 hours post-transduction. Data represent mean arbitrary units (A.U.) in eGFP 
fluorescence between three technical replicates per experiment. Data from each treatment group 
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were normalized to the mean of three non-transduced control wells. Experiments were performed 
at least three times.  
Promoter activation screen 
5x104 84-31.VPR cells were plated into individual wells of 96-well black bottom dishes. 
The following day cells were transfected with 200 ng of sgRNA/reporter plasmid and 1 uL of 
Lipofectamine 2000 (Invitrogen). eGFP fluorescence was quantified at 48 hours post-transfection. 
Data represent the mean arbitrary units (A.U.) of eGFP fluorescence between three technical 
replicates. The screens were performed a total of three times (N=3), and the data from each 
treatment were normalized to the mean of three non-transfected control wells.   
In vivo studies 
C57Bl/6 mice were obtained from the Jackson Laboratory and housed at the University of 
Pennsylvania vivarium and maintained in compliance with the ARVO statement for the Use of 
Animals in Ophthalmic and Vision Research and institutional and federal guidelines under IACUC 
#805890. Subretinal injections were performed as previously described (Dooley et al., 2018). 
Each retina received 1x109 vector genomes in a total volume of 1 uL.  
Immunohistochemistry 
Eyes were enucleated, fixed, and processed as frozen retinal sections as described 
previously. Sections were incubated in blocking buffer consisting of 10% normal goat serum 
(CST) and 2% Triton X-100 (Sigma) and 1xDPBS for 1 hour at room temperature. Next, sections 
were incubated in blocking solution containing rabbit anti-cone arrestin (1:400; Millipore) 
overnight in a humidified chamber at room temperature. Sections were washed three times in 
1xDPBS and incubated in secondary antibody solution consisting of blocking buffer and Cy5-
labeled goat anti-rabbit IgG (1:400; KPL) for 1 hour at room temperature. Sections were washed 
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in 1xDPBS three times and slides were mounted with Fluoromount-G (Southern Biotech) 
containing DAPI.   
RNA isolation and RT-qPCR 
RNA was isolated using the Macherey-Nagel Nucleospin RNA kit. First-strand cDNA 
synthesis was performed using 1000 ng of total RNA with the SuperScript III first-strand synthesis 
system according to manufacturer’s protocol. Real-time PCR was performed with the Applied 
Biosystems 7500 Fast system using the Power SYBR green PCR master mix (Invitrogen). The 
following primer sequences were used: CCACTCCTCCACCTTTGAC (human GAPDH forward), 
ACCCTGTTGCTGTAGCCA (human GAPDH reverse), CGACAACCACTACCTGAGCA (eGFP 
forward), CTTGTACAGCTCGTCCATGC (eGFP reverse). Relative gene expression was 
quantified with the ΔΔCT method and normalized to GAPDH.  
Statistics 
Statistical analyses between two groups were performed using the unpaired student’s t 
test. Comparison of three or more groups were determined to be statistically significant using a 
one-way ANOVA with Turkey’s HSD post-test. A P value of less than 0.05 was considered 
statistically significant. 
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Chapter 5 Discussion 
RGC-directed gene transfer attenuates functional and cellular pathology in experimental optic 
neuritis 
Chapter 2 explored the effects of SIRT1 or NRF2 gene transfer in experimental optic 
neuritis. Under cellular conditions of redox equilibrium, NRF2 is sequestered within the cytoplasm 
and subject to proteasomal-mediated degradation (Dinkova-Kastova et al., 2002; Itoh et al., 2003; 
McMahon et al., 2003). During oxidative challenge, modifications to critical binding proteins free 
NRF2 to translocate into the nucleus, recruit transcriptional machinery to antioxidant response 
elements (AREs), and stimulate transcription of target genes associated with antioxidant defense 
and cellular detoxification (Johnson et al., 2015). SIRT1 is recruited to the nucleus and other 
cellular compartments where it modulates the activity of various protein targets. SIRT1 is known 
to deacetylate and inhibit the transcription factor, p53, thereby downregulating apoptotic gene 
expression and thus improving cell viability (Luo et al., 2001). SIRT1 promotes mitochondrial 
function and antioxidant metabolism by activating PGC-1α, a master transcriptional regulator of 
these responses (Nemoto et al., 2005). While SIRT1 and NRF2 are typically believed to function 
via separate pathways, recent evidence suggests SIRT1 involvement in regulating the expression 
and activation of NRF2 (Ding et al., 2016). In addition, treatment with pharmacological agents 
such as resveratrol, a known activator of SIRT1, was shown to enhance NRF2 expression and 
activity of its downstream effectors (Zhang et al., 2016; Xia et al., 2017). We hypothesized that 
gene augmentation of NRF2 or SIRT1 within RGCs could ameliorate pathological features of 
experimental optic neuritis. Our data demonstrates distinct effects upon RGC survival and 
function following AAV2-mediated overexpression of NRF2 or SIRT1, suggesting these candidate 
factors promote neuroprotective mechanisms that may modify MS pathogenesis.   
RGC-directed gene therapy with SIRT1 and NRF2 vectors revealed differential effects 
upon visual acuity during EAE. Visual acuity was not affected prior to EAE development with any 
of the vectors tested, suggesting vector delivery or transgene overexpression did not mediate 
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unintended toxicity on retinal function. We observed a statistically significant decline in visual 
acuity beginning at day 21 post-immunization with all AAV2 and vehicle treated animals subjected 
to EAE, whereas sham-induced cohorts presented robust responses throughout the experimental 
timeline. While Larabee et al. (2016) reported that NRF2 knockout mice exhibit increased visual 
decline compared to wild-type cohorts during EAE, augmenting NRF2 activity with AAV2 gene 
transfer was unable to preserve visual acuity in the current study. Failure to reverse effects of 
knockout studies may be due to the limited number of RGCs (21%) infected with the AAV2 
vectors in this study. However, interestingly, overexpression of SIRT1 mediated a trending 
increase in functional recovery beginning at day 28 post-induction compared to vehicle and 
AAV2.eGFP control groups subjected to EAE. This protective effect achieved statistical 
significance compared to the AAV2.eGFP control group at 35 and 42 days post-induction, which 
is remarkable given that only a subset of RGCs were infected. This finding also correlates with 
prior investigations utilizing compounds that stimulate SIRT1 activity and demonstrate varying 
degrees of OKR preservation in the context of experimental optic neuritis as well as optic nerve 
crush (Shindler et al., 2007; Fonseca-Kelly et al., 2012; Zuo et al., 2013).  
RGC numbers were significantly reduced in all animal groups sensitized to EAE. 
However, we observed increased RGC numbers with SIRT1 and NRF2 gene augmentation 
compared to the AAV2.eGFP and vehicle treatment groups. SIRT1 gene transfer did not mediate 
a statistically significant increase in RGC numbers but only a positive trend in survival compared 
to EAE-induced controls. NRF2 gene transfer provided the most robust protective response with 
respect to total and regional RGC survival. This outcome is particularly interesting as NRF2 
augmentation did not correlate with an improvement in retinal function as shown by OKR 
recordings. However, disparities between OKR and RGC survival have been previously 
documented in this model (Fonseca-Kelly et al., 2012). Another explanation for this finding could 
be that NRF2 overexpression is simply supporting survival of the RGC cells bodies but unable to 
sustain function. This finding coincides with the inability of NRF2 gene augmentation to 
ameliorate ongoing inflammation and demyelination of the optic nerve, thus providing another 
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explanation for the discrepancy between functional and cellular preservation. This interpretation is 
also consistent with findings by Xiong et al. (2015) where NRF2 gene transfer mediated transient 
yet significant preservation of RGCs following optic nerve crush without promoting axonal 
regeneration required for functional retention. Importantly, as indicated above, we only achieved 
approximately 21% RGC transduction with the AAV2 vector and previously described dose. 
Regarding the discrepancy between OKR preservation and RGC survival following AAV2.SIRT1 
treatment, it is also possible that SIRT1 augmentation may influence the survival of ON direction-
selective ganglion cells, which is the subset of cells that contribute to the OKR, but not mediate a 
statistically significant effect upon total RGC survival (Sugita et al., 2013). Moreover, selection of 
a vector platform with enhanced capabilities for RGC transduction may provide a more potent 
means of cellular protection and functional preservation in this model. Recent developments 
utilizing rational design and in vivo selection have generated novel AAV capsids with improved 
potency and tropism for retinal cell types compared to naturally isolated serotypes such as AAV2 
(Cronin et al., 2014; Choudhury et al., 2016; Zinn et al., 2015; Deverman et al., 2016). Further 
investigation into SIRT1 or NRF2-mediated neuroprotection in this model with an improved vector 
system is certainly warranted. The differential effects observed here also suggest a potential role 
for combined therapy with overexpression of both SIRT1 and NRF2. Due to limitations of the 
current transduction efficiency and the total volume that can be injected in the eye, co-injection of 
both vectors is not feasible, but future development of improved vector systems may allow 
investigation of a dual therapy. 
While we did observe evidence of neuroprotection upon RGC function and viability, 
overexpression of neither NRF2 nor SIRT1 was able to suppress the inflammatory and 
demyelinating phenotype associated with optic neuritis. RGC directed gene therapy did not 
influence immune recruitment to the optic nerve as shown by H&E histological analysis. This 
observation correlates with previous studies that examined small molecule-mediated 
neuroprotection during EAE. Specifically, pharmacological activators of SIRT1, including 
resveratrol and related compounds, did not suppress inflammation in the spinal cord or optic 
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nerve when administered at various doses in the same EAE model (Fonseca-Kelly et al., 2012) 
used in the current study. Interestingly, transgenic overexpression of human SIRT1 within 
neurons was able to reduce inflammation within spinal cord lesions (Nimmagadda et al., 2013). 
Similar to the effects on immunomodulation, AAV2-mediated expression of NRF2 or SIRT1 did 
not alleviate optic nerve demyelination. While these approaches did not attenuate demyelination, 
other studies that examined antioxidant or mitochondrial-directed gene therapy strategies during 
EAE have shown preserved myelin in the optic nerve (Qi et al., 2007; Qi & Lewin et al., 2007; 
Talla et al., 2013; Talla et al., 2014; Talla et al., 2015). However, discrepancies in animal models, 
EAE immunization protocols, and other components of study design limit a direct comparison with 
these reports. In addition, our findings with respect to inflammation and myelination may once 
again reflect the limited transduction efficiency of the AAV2 vector.  
Collectively, this study demonstrates at least partial neuroprotective effects of NRF2 and 
SIRT1 gene augmentation in the context of experimental optic neuritis, and suggests an 
important role of these signals in MS pathogenesis. Moreover, the results underscore the 
therapeutic potential of targeting conserved cell survival pathways or mechanisms to impede 
progression of complex neurodegenerative disease. Downstream investigations will determine 
the optimal combinations of promoter elements (ex. CAG, SNCG, CMV, CBh), AAV capsids (ex. 
AAV2, AAV7m8, AAV2 tyrosine mutants), and transgenes (native versus codon-optimized) to 
improve RGC targeting efficiency.  
Stimulation of the mTOR signaling pathway with AAV-mediated gene augmentation promotes 
divergent effects upon photoreceptor neuroprotection in a pre-clinical model of retinitis 
pigmentosa 
Chapter 3 examined the therapeutic potential of reprogramming cell metabolism in a pre-
clinical model of inherited vision loss following stimulation of the mTOR pathway with AAV-
mediated gene augmentation. The exact role of mTOR signaling in the context of 
neurodegenerative disease remains an intense topic of debate. Several lines of evidence suggest 
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that downregulation of mTOR activity via treatment with the canonical mTOR inhibitor, rapamycin, 
can attenuate pathological mechanisms in several models of neurodegeneration including 
Parkinson’s disease, Huntington’s disease, and Alzheimer’s disease (Ravikumar et al., 2004; 
Malagelada et al., 2010; Spilman et al., 2010; Bove et al., 2011). Conversely, other investigations 
suggest stimulation of the insulin/AKT/mTOR axis can mediate beneficial outcomes in related 
neurodegenerative disease models (Ries et al., 2006; Kim et al., 2012; Lee et al., 2015). In the 
present study, targeting the mTOR pathway at two separate points of regulation led to divergent 
effects upon photoreceptor survival, structural integrity, and visual function, thus emphasizing the 
complex nature of re-wiring cell metabolism for therapeutic intent.  
Several studies highlight the protective potential of targeting Rheb activation to improve 
therapeutic outcomes in the context of neurodegenerative disease models (Kim et al., 2012; Lee 
et al., 2015; Lim et al., 2016; Wu 2016, Wu 2017). Stimulating the mTOR pathway at this 
downstream point of regulation with caRheb gene augmentation did not mediate a notable 
protective effect in the Pde6brd10 retina. Interestingly, AAV.caRheb vectors demonstrated potent 
stimulation of mTORC1 activity in vitro showing enhanced expression of the canonical mTORC1 
activation marker, pS6. However, this activity did not translate in vivo as shown by negative 
immunostaining for the pS6 in retinal sections overexpressing the caRheb transgene. This 
suggests the presence of mechanisms in place to inhibit caRheb’s capacity to stimulate mTORC1 
within photoreceptors or limited ability to detect increased expression of this marker in vivo. 
These observations diverge from previous studies in which caRheb gene transfer sufficiently 
stimulated mTORC1 activity within various neuronal populations and conferred stress resistance 
in models of Parkinson’s disease, Huntingtin’s disease, and optic nerve trauma (Kim et al., 2012; 
Lee et al., 2015; Lim et al., 2016). Other lines of evidence suggest Rheb may play a competing 
role in promoting cell death signaling programs in response to different forms of cellular stress 
(Potheraveedu et al., 2017). UV or TNFα-induced cellular stress combined with Rheb 
overexpression enhanced apoptotic signaling in vitro, whereas Rheb knockdown or treatment 
with rapamycin provided partial protection from these cytotoxic agents (Karassek et al., 2010). In 
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the context of retinal degeneration, light-induced damage of retinal ganglion cells (RGCs) led to 
upregulation in Rheb expression that associated with an increase in markers of apoptosis prior to 
degeneration (Shu et al., 2014). Taken together, the protective or pro-apoptotic functions of Rheb 
are likely determined by mechanisms elicited through the specific pathology in question. 
Moreover, amplifying Rheb activity with gene transfer likely modulates divergent effects upon cell 
biology depending on the particular disease context.   
AKT3 was selected based on a previous report demonstrating its increased capacity to 
stimulate mTORC1 activity compared to other AKT variants within retinal cell types (Miao et al., 
2016). In addition, targeted ablation of AKT3, but not AKT1 or AKT2, leads to severe 
neurodevelopmental defects including reduced brain and neuron size suggesting a unique role for 
this variant in neuronal homeostasis (Easton et al., 2005). AKT3 augmentation with AAV vectors 
stimulated a potent neuroprotective effect upon photoreceptor survival and morphological 
preservation. This protective effect was associated with stimulation of mTORC1 and mTORC2 in 
regions of the retina specifically transduced with the AAV.AKT3 vector. While the role of 
mTORC1 has been extensively evaluated in RP disease models (Venkatesh et al., 2015; Zhang 
et al., 2016), our findings are the first to report upregulation in mTORC2 signaling activity 
associated with photoreceptor neuroprotection. This data deviates from previous observations by 
Venkatesh et al. (2015) in which mTORC2 activity was decreased following transgenic ablation of 
Pten and increased cone survival in the Pde6brd1 mouse retina. Downstream investigations to 
delineate the specific contributions of mTORC1 and mTORC2 in mediating photoreceptor survival 
in pre-clinical models of IRD will be necessary.  
Despite the dramatic cellular preservation mediated by AKT3 gene augmentation, we 
observed differential effects upon functional preservation following evaluation with 
electroretinography and OKR. We observed statistically significant preservation of the mixed rod-
cone a-wave and b-wave responses in eyes treated with AAV.AKT3 at the PN30 measurement 
but not during later stage degeneration. Despite the morphological preservation of cone structure 
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with AAV.AKT3 treatment, we did not observe an improvement in cone-specific light responses 
compared to controls at any of the time points tested. This finding deviates from prior 
investigations that examined strategies of cone photoreceptor neuroprotection in similar disease 
models. These differences may be explained by variations in study design with respect not only to 
the transgene cassette but vector dose, injection route, kinetics of degeneration, and timing of 
vector delivery. In the present study, vectors were injected at a time point just prior to the onset of 
photoreceptor death, whereas previous investigations administered the experimental intervention 
immediately after birth and prior to retinal maturation and onset of disease mechanisms (Xiong et 
al., 2015). These differences in experimental design likely have important downstream 
implications relevant to retinal coverage, kinetics of vector recruitment and expression in relation 
to onset of neurodegenerative mechanisms, and ultimately therapeutic outcome measures.  
Interestingly, we observed histological features that suggest enhanced müller cell 
activation within regions of the Pde6brd10 retina specifically transduced with the AAV.AKT3 vector. 
Reactive gliosis is a response typically associated with tissue injury where these cells become 
activated and proliferate to mediate various functions including tissue remodeling, neurotrophic 
factor release, scavenging of cellular debris (Bringmann et al., 2009; Goldman, 2014; 
Reichenbach et al., 2013). While this response is intended to suppress further retinal damage, 
chronic activation may be detrimental to neighboring cells and disrupt retinal homeostasis. For 
example, activated müller cells have been observed to upregulate expression and secretion 
various pro-inflammatory molecules including tumor necrosis factor (TNF) and monocyte 
chemoattractant protein (MCP-1). Furthermore, they are known to secrete excess amounts of 
nitric oxide (NO) which generates free radicals that may be damaging to neighboring cells 
(Bringmann et al., 2009). Long-term expression of AAV.AKT3 in the wild-type mouse retina was 
accompanied with extensive retinal disorganization and loss of cellular structures in regions 
specific to the subretinal bleb. Conversely, animals injected with the reporter vector alone 
demonstrate normal retinal architecture. Moreover, wild-type animals treated with AAV.AKT3 also 
demonstrate enhanced histological markers indicative of chronic reactive gliosis. Interestingly, I 
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did not observe histological hallmarks of reactive gliosis in Pde6brd10 retinal samples treated with 
GRK1-driven AKT3 vectors. This finding suggests the chronic muller cell activation was a 
byproduct of off target transgene expression within these cells types when exposed to vectors 
driven by the ubiquitous CAG promoter. Overall, these findings caution detailed investigation to 
accurately define how other retinal cell types respond to neuroprotective reagents beyond 
examination of the primary cellular targets exhibiting pathology.  
Advancement of gene therapies based on strategies to reprogram cell metabolism must 
be met with highly stringent safety criteria prior to clinical translation. While we did not observe 
evidence of tumor formation, long-term overexpression of AKT3 in wild-type animals led to 
extensive retinal disorganization and loss of photoreceptor structure. This finding is unsurprising 
as cells require a delicate balance in these metabolic components to accommodate their precise 
physiological demands. Determining and achieving this balance with gene augmentation or 
silencing strategies will be an enormous challenge in translating these approaches to the clinic. 
Additional regulatory elements, such as stress-responsive promoters or inducible systems, will 
likely play critical roles in the clinical development of neuroprotective gene transfer strategies 
based on cellular reprogramming. For example, Fujita et al. (2017) developed an AAV vector that 
combined NRF2 gene augmentation with the stress-inducible Mcp-1 promoter to provide spatial 
and temporal regulation of transgene expression. Other inducible systems built upon features of 
the Lac or Tet operon have been incorporated within AAV expression cassettes for regulation of 
vector expression via small molecule induction (Santiago et al., 2018; Sochor et al., 2015; Zhong 
et al., 2016). Coupling such elements with AKT gene expression may allow “fine tuning” of 
downstream metabolic pathways and, importantly, provide a molecular safety switch in the event 
of genotoxicity or oncogenic transformation.    
  Collectively, this investigation demonstrates a broadly protective effect upon 
photoreceptor viability and structure following gene augmentation in a model of inherited retinal 
degeneration. These findings underscore the importance of AKT activity and downstream 
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pathways associated with anabolic metabolism in photoreceptor survival and maintenance. 
Furthermore, it emphasizes the complex and delicate nature of reprogramming cell metabolism 
as well as important safety concerns in arresting progression of complex neurodegenerative 
disease with “generic” gene therapy strategies.   
 
CRISPR/Cas9 transcriptional activation stimulates tissue-specific promoter activity from AAV 
vectors 
Various commercial reagents are available to enhance plasmid transfection or AAV 
transduction within non-permissive primary cells and stem cells. While these tools are valuable to 
increase overall levels of gene transfer efficiency, these reagents will likely provide minimal 
advantages if the transgene is controlled by a tissue or cell-specific regulatory element. Other 
investigations highlight the use of pharmacological reagents to stimulate endogenous promoter 
activity, which may provide a possible avenue to improve in vitro potency of tissue-restricted 
vectors. For example, Li et al. (2002) identified a region of the cone arrestin promoter sequence 
that is responsive to retinoic acid. However, effects upon transgene expression are likely transient 
due to the limited half-life of the compound. In addition, it is unclear what impact different 
pharmacological reagents may exert upon cell biology. It may also be possible to amplify 
transgenic promoter activity by overexpressing transcription factors known to act upon the DNA 
sequence of interest. However, transcription factors typically act upon networks of associated 
genetic elements, thereby imposing a non-specific response. Similar to pharmacological 
induction, it is unclear how transcriptional reprogramming will affect underlying cell biology and 
other downstream parameters of the potency assay. The present approach utilizing dCas9-based 
gene activation provides a highly potent, stable, and precise platform to stimulate cell-specific 
promoters from AAV vectors.  
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Supplementing dCas9 activation with AAVR co-expression provided a highly effective 
means to improve vector performance and thereby increase levels of tissue-specific promoter 
transgene expression. Specifically, AAVR overexpression dramatically enhanced AAV8 uptake in 
cell lines harboring both GRK1 or CAR promoter activation systems. Interestingly, we observed 
differential effects upon capsid uptake with AAVR overexpression using a panel of eleven distinct 
serotypes suggesting capsid or cell-type dependent effects upon AAV entry. For example, AAVR 
overexpression within 84-31 cells greatly reduced expression of vectors such as AAV7m8 and 
AAV3. However, expression of these vectors was greatly enhanced in ARPE-19.AAVR cells 
compared to control cell lines (data not shown). While AAVR is certainly a major determinant of 
AAV entry, other distinct mechanisms likely influence the process of viral transduction at various 
steps. It is possible that AAVR overexpression could perturb such mechanisms in a cell line 
dependent fashion thus disrupting certain molecular events relevant to capsid binding to cellular 
receptors/co-receptors, endocytosis, or nuclear transport.  
Altogether, this study outlines a broadly applicable approach for engineering cell lines to 
express AAV vectors regulated by tissue-specific promoters. While our data demonstrate the 
utility of this approach in the context of retinal-specific regulatory elements, this strategy may be 
applied broadly to other promoter sequences that display specific activity within a tissue or cell 
population of interest. Furthermore, continued identification and engineering of Cas proteins with 
broader PAM recognition features and enhanced DNA binding specificity will allow the continued 
improvement of such systems. Current and future directions of this investigation involve utilizing 
these cell lines for the design and implementation of gene therapy vector potency assays that 
address numerous inherited retinal disease targets.       
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